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Abstract
Hematopoietic stem cells (HSCs) hold great promise for the treatment of disease. The
rare frequency at which HSCs occur in the bone marrow under homeostatic condi-
tions is a limiting factor in both their study and clinical use. ex vivo expansion of
these cells is therefore a necessary step to maximizing their potential. In this thesis I
explore the concept that signals from the extracellular matrix can direct differentia-
tion, survival and self-renewal decisions in hematopoietic cells, and thus can provide
a foundation for the design of ex vivo expansion strategies. This work is focused
on the role integrins, the major class of cell-extracellular matrix adhesion molecules,
play in mediating these signals to hematopoietic cells at two developmental stages.
In the erythroid lineage, I show that expansion of committed erythroid progenitors
is regulated by growth factor and integrin-mediated signals in temporally distinct
regimes. I establish a biologically relevant role for a 40 1 but not a5 01 integrins in
erythropoiesis and provide evidence that erythroid differentiation and expansion are
regulated by separate processes. In the study of uncommitted HSCs, I identify several
integrin subunits that are differentially expressed on highly purified HSC populations
that correlate with long term repopulating ability. One of these subunits, a2 in-
tegrin, specifically mediates adhesion of HSCs to bone marrow extracellular matrix
proteins, thereby providing a potential mechanism for stem cell self-renewal. This
work establishes that integrin-mediated interactions between hematopoietic cells and
the extracellular matrix are dynamic and provide important developmental cues.
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Title: Professor
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Chapter 1
Introduction
Cell behavior is influenced by a combination of cues from soluble growth factors,
the extracellular matrix and neighboring cells. Recent advances in the study of
hematopoiesis have focused the field on the importance of interactions with the niche
in directing cellular differentiation and survival [41]. In this thesis, I explored the
idea that the extracellular matrix is an active component of the hematopoietic niche
in that cellular adhesion to matrix proteins influences cell differentiation and survival
decisions. In particular, I focused on the role that integrins, a broad class of cell
surface adhesive proteins, play in hematopoiesis. Chapter 1 provides a concise review
of hematopoiesis and integrin structure and function. The major focus of my thesis
work was on growth factor and integrin-mediated regulation of erythropoiesis, which
is presented in Chapters 2 and 3. The focus of Chapter 4 shifts towards integrins on
self-renewing hematopoietic stem cells (HSCs). Chapter 5 discusses the relevance of
this work within the field and suggests avenues for further investigation.
1.1 Motivations
Since the landmark discovery of bone marrow cells with the capacity for both self-
renewal and differentiation [6], there has been much interest in precisely defining the
characteristics of these so-called hematopoietic stem cells. The ability of these cells
to develop into any type of blood cell while at the same time maintaining self-renewal
capacity in at least some of the progeny holds great promise for the treatment of
hematopoietic disease. Hematopoietic stem cells are routinely used in bone marrow
transplants for the treatment of cancers and inherited immune disorders. In the
future, HSCs may be used in combination with gene therapy to correct monogenetic
hematological disorders or even to endow HSCs with enhanced properties [48].
The rare frequency at which HSCs occur in the bone marrow under homeostatic
conditions, 1 in 100,000 in the adult human [95], is a limiting factor in both their
study and clinical use. ex vivo expansion of these cells is therefore a necessary step
to maximizing their potential. To this end, much effort in the last decade has been
dedicated to developing a cytokine cocktail to stimulate stem cell self-renewal in vitro,
with relatively little attention to cues that may come from the extracellular matrix.
With a more detailed, mechanistic understanding of how hematopoietic cells interact
with their environments we can better realize the therapeutic potential of these cells.
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Figure 1-1: Schematic of the adult hematopoietic hierarchy. Reprinted from
Lodish et al, with permission.
1.2 Hematopoietic development
Blood is among the most highly self-renewing tissues in the body, producing on order
10" new cells each day in an adult. This self-renewing capacity depends upon a
constant source of hematopoietic stem cells, which arise from the mesoderm in the
developing embryo shortly after gastrulation. In mice, these first hematopoietic cells
are found in the extra-embryonic yolk sac at around embryonic day 7.5 and most
likely contribute to embryonic red cell production, or primitive hematopoiesis. Some
of these cells migrate to the aorta-gonad-mesonephros region, where the first definitive
hematopoietic stem cells are found around E8.5. Circulating HSCs from the yolk sac
and perhaps other sites begin to seed the fetal liver at E9.5-10.5, from which point
on the fetal liver functions as the primary hematopoietic organ until just after birth
[96].
Developing hematopoietic cells are thus exposed to a variety of microenvironments
in the fetus. This compartmentalization of fetal hematopoiesis serves the developing
embryo's dual needs for mature as well as primitive cells. Some anatomical sites pro-
vide inductive signals for production of functional red blood cells for immediate use,
while others support the proliferation of undifferentiated HSCs to serve the embryo
in the future.
In the adult, steady state hematopoiesis occurs in the bone marrow. The hard
exterior of calcified bone protects these critical cells from injury while the highly
vascularized interior allows access to circulating growth factors as well a mechanism
for transport of differentiated cells to the tissues. Under extreme stress conditions,
extramedullary hematopoiesis can occur, most often in the spleen. In addition, at
any given time, a small number of HSCs can be found in the circulation [88].
1.3 Hematopoietic niches
1.3.1 Endosteal niche
The bone marrow is the primary source of HSCs in the adult. In recent years, much
progress has been made in defining the bone marrow HSC niche and importantly,
the mechanism through which it supports stem cell self -renewal and differentiation.
Current thinking allows for at least two distinct niches within the bone marrow, an
endosteal niche and a vascular niche; further defining their relative roles and potential
interaction remains a major challenge.
The first evidence that hematopoietic cells may develop within specific microen-
vironments in the bone marrow came in 1975 when Lord and Testa found an unequal
distribution of HSCs in the bone marrow [44]. Bone marrow samples taken from the
endosteal surface of mouse femurs had greater spleen repopulating ability than did
those from the center of the marrow. Soon after, Schofield first proposed the con-
cept of a hematopoietic stem cell niche, wherein cell-cell intereactions allow stem cell
self-renewal but prohibit differentiation [67].
More recently, two independent approaches have provided evidence for an inter-
action between HSCs and the osteoblasts that line the endosteal surface. Genetically
increasing the number of osteoblasts by expressing a constitutively active form of
parathyroid hormone (PTH) or the PTH/PTH-related protein receptor, both posi-
tive regulators of osteogenesis, resulted in a concommitant increase in the number of
HSCs [9]. A second group arrived at the same result by knocking down expression of
bone morphogenetic protein receptor 1A, a negative regulator of osteogenesis which
is normally expressed on endosteal osteoblasts [93]. In addition, both studies provide
evidence for a direct, physical interaction between HSCs and osteoblasts.
1.3.2 Vascular niche
Despite the landmark work in identifying ostoblastic niches for HSCs, the fact that
hematopoiesis can take place in extramedullary sites, in the absence of osteoblasts,
implies that other supportive HSC niches also exist. The derivation of HSCs and
endothelial cells from a common progenitor, the hemangioblast, suggests the existence
of an endothelial HSC niche.
Recent advances in HSC purification have enabled in situ imaging of HSCs and
revealed possible endothelial niches [34]. This purification strategy takes advantage
of a family of receptors that are differentially expressed among functionally distinct
progenitor cells. Using this code, competitive reconstitution analysis indicated that
1 in 2.1 CD150+CD48-Sca-1+lineage c-kit+ cells were true long-term repopulating
HSCs, the best purification to date. This same population of cells was found asso-
ciated with the sinusoidal endothelium in spleens of animals treated with G-CSF to
mobilize stem cells. Similarly, in the bone marrow, 60% of these cells that were im-
aged were in contact with sinusoidal endothelium. Consistent with this, endothelial
cells isolated from heart and liver were able to maintain HSC activity in vitro [40].
Together, these data provide strong evidence for an endothelial niche for HSCs in the
bone marrow and other hematopoietic tissues.
One prominent model linking the endosteal and vascular niches proposes that the
endosteal niche provides a microenvironment suited to quiescence and HSC mainte-
nance, while the vascular niche promotes proliferation and differentiation [38]. These
niches are discussed in more detail in Chapter 4 and Chapter 5.
1.4 ex vivo HSC expansion
The area of stem cell biology with the most fervent activity has been identifica-
tion of growth factors to support HSC expansion in culture. Most successfully, this
has involved identification of factors secreted by primary stromal cells that support
HSC expansion in co-culture experiments [91]. This approach led to the isolation of
angiopoietin-like proteins, which support up to a 30-fold net expansion of long term
HSCs. Progress in this realm can be combined with developments in culture systems,
bioreactors and biomaterials to expand HSCs. Notably, low oxygen conditions in
culture seem to promote HSC activity [14], which is attributed to their hypoxic envi-
ronment in vivo [52]. In addition, advances in biomaterials have made it possible to
culture stem cells on substrates that present ligands to specifically activate signaling
pathways [75].
Another approach to expanding stem cells is to create HSCs from pluripotent
embryonic stem cells. Because ES cells can be maintained in culture without differ-
entiation, they represent an attractive source for HSCs. The most impressive results
towards this end thus far have been obtained by overexpressing key hematopoietic
transcription factors in mouse ES cells [84]. Expression of Cdx4 and HoxB4 together
in ES cells led to commitment to hematopoietic mesoderm, and, importantly, devel-
opment of both lymphoid and myeloid cells in a transplant model. However, much is
still unknown about the transcriptional programs that control hematopoietic differen-
tiation and self-renewal and how such genetic modification could impact the ultimate
cell behavior. Influencing cell behavior by controlling the microenvironment therefore
offers a safer approach to generation of large numbers of HSCs.
1.5 Overview of integrins
Integrins are the major class of cell-matrix adhesion molecules. Integrins are a3
heterodimeric molecules formed by combinations of 8 3 subunits and 18 a subunits.
Most integrins recognize several different ECM proteins, and individual matrix pro-
teins can bind to several integrins [27]. Through their characteristic bidirectional
signaling mechanism, integrins allow for exquisite coordination of the external and
internal environments of the cell [20]. Furthermore, the interactions of integrins with
soluble growth factors allow for another level of control [17]. Not surprisingly, inte-
grins are involved with a wide variety of cellular processes, including control of cell
growth, shape, survival and cell cycle progression. Integrins are highly developmen-
tally regulated, again allowing for a dynamic relationship between the cell and its
environment.
Integrins play a major role in hematopoiesis, the #1 subunit in particular. #1null
embryos have significant defects in migration of hematopoietic cells to the fetal liver
and other sites of hematopoiesis [8] and adult #1null hematopoietic progenitors gen-
erated using a conditional knockout system were not able to repopulate primary sites
of hematopoeisis [58]. The 01 subunit can dimerize with 10 different a subunits (ai
through ag and a,) leading to much variety in the ligands with which it can interact.
/31 integrins are thought to be expressed on all hematopoietic cells, so changes in
expression of the a subunit could be a mechanism by which cells at different stages
modulate their interaction with different matrix molecules.
1.6 Discussion
The overall motivation for this thesis is the idea that adhesive interactions on hematopoi-
etic cells are dynamic, responding to the unique needs of cells at distinct develop-
mental stages. In approaching this project, I first focused on the erythroid lineage.
In Chapter 2 I present data to support a model where erythropoiesis is regulated by
growth factor- and integrin-mediated signals in temporally distinct regimes. In Chap-
ter 3, the downstream signaling pathways behind the observed cellular behavior are
explored. In Chapter 4, the focus shifts toward expression and function of integrins
on hematopoietic stem cells. In Chapter 5, I discuss the relevance of this work within
in the field of stem cell biology and present thoughts on future directions.
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Chapter 2
Growth factor and extracellular
matrix-mediated regulation of
erythropoiesis
2.1 Introduction
Erythropoietin (Epo) has long been understood to be the major factor governing ery-
thropoiesis; its role in regulating expansion, differentiation, apoptosis and activation
of erythroid-specific genes is well characterized [62]. The first phase of erythroid dif-
ferentiation is highly Epo-dependent, whereas later stages are no longer dependent on
Epo [39]. Consistent with this, Epo receptors are downregulated as erythroid progen-
itors undergo terminal expansion and differentiation [94]. This raises the question of
what other signals, if any, these differentiating erythroblasts require to support ter-
minal expansion, differentiation, and enucleation. The extracellular matrix protein
fibronectin has been identified as an important part of the erythroid niche in both
the adult bone marrow and fetal liver [74], but its precise role in erythropoisis and
potential interaction with Epo-mediated signals was unknown.
I sought to characterize the precise role that fibronectin plays in erythropoiesis
by utilizing an in vitro model of fetal erythropoiesis [94]. In this system, populations
of erythroid progenitors at varying phases of differentiation are purified from fetal
liver based on expression of the cell surface markers CD71 and TER119; these same
markers can then be used to track differentiation of progenitors cells cultured in vitro.
I present data to support a novel model for erythropoiesis wherein Epo and fibronectin
each play a distinct, essential role. My work shows that erythroid expansion proceeds
in two phases, with an early Epo-dependent phase followed by fibronectin-dependent
phase.
2.2 in vitro model of fetal erythropoiesis
In mammals, definitive erythropoiesis first occurs in the fetal liver with progeni-
tor cells from the yolk sac [51]. Within the fetal liver and the adult bone marrow,
hematopoietic cells are formed continuously from a small population of pluripotent
stem cells that generate progenitors committed to one or a few hematopoietic lin-
eages. In the erythroid lineage, the earliest committed progenitors identified ex vivo
are the slowly proliferating burst-forming unit-erythroids (BFU-E) [22, 23]. Early
BFU-E cells divide and further differentiate through the mature BFU-E stage into
rapidly dividing colony-forming unit-erythroids (CFU-E) [22, 23]. CFU-E progenitors
divide three to five times over two to three days as they differentiate and undergo
many significant changes including decrease in cell size, chromatin condensation and
hemoglobinization leading up to enucleation and expulsion of other organelles [96].
These changes are used to define the sequential stages of erythroid differentiation:
proerythroblasts, basophilic and polychromatophilic erythroblasts, orthochromatic
erythroblasts and reticulocytes. Earlier work in the lab used the sequential devel-
opmental upregulation of CD71, induction of TER119, and then downregulation of
CD71 as a tool for monitoring these stages of erythroid differentiation by flow cytom-
etry both during culture in vitro and in vivo [71, 94]. This work formed the basis for
the in vitro model I used to study erythropoiesis.
Fetal liver erythroid cells can be separated into five distinct populations of pro-
gressively differentiated cells based on expression of CD71, the transferrin receptor,
and TER119, an erythroid-specific glycoprotein (Figure 2-1). Early erythroid progen-
itors, the R1 population, express moderate levels of CD71 and are TER119-. Later
progenitor cells, R2, express higher levels of CD71 but are still TER119-. As cells
continue to divide and differentiate, TER119 expression is induced and then CD71
expression is downregulated, as indicated by the R3, R4 and R5 populations. R3-R5
populations contain no CFU-E activity [94].
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Figure 2-1: Five populations of sequentially differentiated erythroid cells
can be isolated from Day 14.5 fetal liver based on expression of CD71 and
TER119. R1 and R2 populations contain all of the CFU-E activity.
Expression of CD71 and TER119 can also be used to track erythroid differenti-
ation in vitro. In this culture system, purified Day 14.5 TER119- progenitor cells
are cultured on fibronectin-coated plates in two phases: first in the presence of ery-
thropoietin for 16-18 hours and then without Epo for an additional 24 hours. On
each day, cells are dissociated with PBS containing EDTA and stained with CD71
and TER119 antibodies for analysis by flow cytometry. In the first phase, CD71 is
upregulated and there is modest expansion in cell number. By Day 3, TER119 is
upregulated and CD71 is downregulated, recapitulating the staining pattern seen in
freshly isolated fetal liver cells (Figure 2-2).
Day 0 Day 1 Day 2 Oay 3
FITC CD7L
PE TERI19
Figure 2-2: CD71 and TER119 can be used as markers of erythroid dif-
ferentiation in vitro. TER119- cells were cultured on fibronectin-coated plates
in Epo-containing media for one day and in Epo-free media for two additional days.
Over three days, the staining pattern recapitulates that seen in freshly isolated fetal
liver.
2.3 Role of fibronectin in erythropoiesis
2.3.1 Background
Fibronectin is a ubiquitous extracellular matrix molecule that presents developmen-
tal cues to many cell types, including hematopoietic cells [28]. Interactions with
fibronectin are essential for proper erythropoiesis, as adhesion to fibronectin is re-
quired for enucleation of murine erythroleukemia cells to form reticulocytes [53]. Hu-
man bone marrow erythroid progenitor cells expand in the presence of fibronectin
in a dose-dependent manner, and do not form enucleated erythroid colonies in the
absence of fibronectin [86]. Taken together, these findings suggest that fibronectin
not only provides a supportive niche for erythroid progenitor cells but also plays a
role in ensuring proper terminal expansion and differentiation.
2.3.2 Two-stage model for erythroid expansion
I used the in vitro model described above to study the role of fibronectin in erythro-
poiesis. I observed a dramatic increase in cell number between Day 1 and Day 2 for
TER119- progenitor cells cultured on fibronectin, but not on an uncoated substrate,
despite the presence of Epo between Day 0 and Day 1 in both cases (Figure 2-3, solid
lines). As previously shown, withdrawal of Epo during the first day of culture led to
an expansion defect, even in the presence of fibronectin (Figure 2-3, dashed lines).
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Figure 2-3: Fibronectin supports expansion of erythroid progenitors.
TER119~ cells were cultured on fibronectin-coated or control wells in Epo-containing
media for one day and in Epo-free media for a second day (solid lines) or without Epo
at all (dashed lines). In the presence of Epo, progenitor cells cultured on fibronectin
undergo dramatic expansion in cell number but cells cultured on a control substrate
do not. Withdrawal of Epo during the first day of culture results in an expansion
defect regardless of the substrate.
This result led to the hypothesis that Epo and fibronectin regulate erythroid ex-
pansion in temporally distinct regimes. To test this hypothesis, I varied the presenta-
tion of extracellular matrix and growth factor cues during the course of the two-day
culture period. When TER119- erythroid progenitors were cultured on a control
substrate for one day and then transferred to a fibronectin substrate for the second
day, the level of expansion was indistinguishable from that achieved in the presence of
fibronectin for the entire two-day period, suggesting that fibronectin is only required
during the second day of erythroid culture (Figure 2-4).
In another test, I isolated TER119+ cells from the fetal liver. As described pre-
viously, TER119 is a marker of differentiated erythroid cells [35], so I predicted that
expansion of these cells is fibronectin-dependent but not Epo-dependent. Indeed,
when I cultured differentiated TER119+ erythroid cells I found that they expanded
on fibronectin and not on the control substrate, and that the addition of Epo had no
effect (Figure 2-5). It is important to note that these freshly isolated TER119+ cells
have not been exposed to Epo ex vivo and thus the response can be attributed solely
Day 0 Day 1 Day 2
-- FN transfer to PN
-" PBS transfer to FN
DayD DayI Day2
Figure 2-4: Fibronectin is only required on the second day of culture.
TER119- cells were cultured on fibronectin-coated or control wells in Epo-containing
media for one day and then dissociated and transferred to fresh fibronectin surfaces in
Epo-free media for a second day. A dramatic expansion in cell number was observed
regardless of which substrate was present on the first day of culture.
to the presence of fibronectin.
4-
PBS
'I'-*-- PBS+ErpoED
0
Day 0 Day I
Figure 2-5: TER119+ cells exhibit fibronectin-dependent Epo-independent
growth. TER119+ cells were cultured on fibronectin-coated or control wells in the
absence of Epo. Only those cells cultured on fibronectin expanded; addition of Epo
to the culture media (dashed line) had no effect on cell number.
Similarly, blocking the fibronectin-coated wells with increasing concentrations of
an anti-fibronectin antibody abrogated expansion of TER119+ cells, further indicating
that fibronectin specifically mediates this phase of erythropoiesis (Figure 2-6). Taken
together, these results suggest a two-phase model for erythroid expansion, where the
presence of Epo in the first day of culture followed by the presence of fibronectin in
the second day of culture are each essential to proper erythroid expansion.
4-
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Figure 2-6: Blocking fibronectin with antibodies blocks expansion of
TER119+ cells. TER119+ cells were cultured on fibronectin-coated wells that were
pre-treated with increasing concentrations of anti-fibronectin antibody.
2.4 Role of integrins in erythropoiesis
2.4.1 Background
Given the observed biological significance of fibronectin on erythroid expansion, I
was interested to determine the molecular mediators of this response. Fibronectin
is a large multidomain glycoprotein that contains binding sites for heparin, collagen,
fibrin and gelatin in addition to a number of cell surface receptors. Adhesion of
hematopoietic cells to fibronectin is mediated by at least two integrin pairs. a531
integrin (also known as VLA-5) mediates adhesion to the canonical RGDS sequence
in the tenth type III repeat. There are two cell-binding sequences in the type III
connecting segment (IIICS) that mediate adhesion to a43 1 integrin (also known as
VLA-4). The LDV sequence forms a high affinity binding site, while the REDV
sequence forms a binding site with much lower affinity [26, 37] (Figure 2-7).
a4 integrins appear to be essential for efficient differentiation and expansion of
erythroid progenitors in vivo and in vitro. Deletion of a 4 integrin has no effect on
the number of fetal liver erythroid progenitors, but results in decreased numbers
of differentiated erythroid cells. In in vitro erythropoiesis assays, fetal liver a 4-null
erythroid cells formed only small, pale colonies whereas wild-type cells transmigrated
beneath the stroma, expanded, and formed large red colonies [4]. Early studies have
a51 a401
NH2 EDDWD ELII1Li Lii DW COOH
Type 1 Type Il Type III EIIIAorBf
Figure 2-7: Schematic diagram of fibronectin structure indicating integrin
binding sites.
shown that fetal liver erythroid cells express both a4 and a5 integrins and that these
integrins mediate attachment of CFU-E to fibronectin and to stromal cells [65, 80, 81].
However, the biological significance of this adhesion was not yet known.
2.4.2 Integrin expression
I was interested in determining the molecular mediators of the observed fibronectin re-
sponse, so I focused on integrins as fibronectin receptors. As previously shown, E14.5
fetal liver cells can be separated into five distinct phases of erythroid development
on the basis of relative expression of CD71 and TER119 (Figure 2-1). This system
allowed me to examine expression of candidate fibronectin receptors at distinct phases
in erythropoiesis that correlate with the two-phase model.
I used flow cytometry to determine fibronectin receptor expression on the surface of
fetal liver erythroid progenitors. By co-staining E14.5 fetal liver cells with antibodies
to CD71 and TER119 as well as a panel of integrin subunits, I determined that a4,
a 5 and 31 are the most highly expressed integrins on these cells. Expression of a 2 ,
av, #2 and 33 integrins was not distinguishable from the background fluorescence on
erythroid progenitor RI and R2 cells, a pooled population of progenitors I refer to as
R1+R2 cells (Figure 2-8).
Expression of a 4, a5 and 3 1 integrins is downregulated as cells differentiate (Fig-
ure 2-9). R1+R2 cells express the highest levels of each integrin subunit, and the
expression level in the R3, R4 and R5 populations progressively decreases. While R4
and R5 cells have completely lost expression of a5 integrin, expression of a 4 and #1
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Figure 2-8: a 4, a 5 and /31 integrins are the most highly expressed integrin
subunits on erythroid progenitor R1+R2 cells. Fetal liver cells were stained
with antibodies against CD71, TER119 and a panel of integrin subunits. Cells were
gated into R1+R2 populations and integrin expression (dark trace) was compared to
that of the secondary antibody alone (light trace).
integrin is clearly distinct from the background in these populations. Quantification
of the mean fluorescence intensity of each integrin subunit in these populations is
shown in Figure 2-10.
These data were further confirmed using quantitative PCR. Cells from each region
were sorted and total RNA was isolated. RNA was reverse transcribed using random
primers and amplified using the SYBR Green system. As shown in Figure 2-11, inte-
grin message level decreases during erythroid differentiation. Data were normalized
to 18S ribosomal RNA expression as well as to expression in the R1+R2 population.
Integrins can exist in active and inactive conformations, and only the active con-
formation is available for ligand binding and subsequent downstream signaling [27].
The monoclonal antibodies used above for integrin expression studies do not nec-
essarily detect the active conformation. However, vascular cell adhesion molecule-1
(VCAM-1) is an a 4,31 ligand in vivo [18] and in its soluble form can be used in a
functional assay of a4,31 ligand binding [59]. To test the activity of a 401 integrins on
erythroid progenitors, fetal liver cells were sorted into R1+R2 through R5 populations
as described above. Cells were incubated with increasing amounts of soluble VCAM-
1 in the presence of Mn 2+ for 30 minutes at 4*C. Unbound VCAM was removed
by washing and cells were stained with an anti-VCAM antibody for quantitation by
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Figure 2-9: a4, a 5 and #1 integrin expression is downregulated during ery-
throid differentiation. Fetal livers were stained with antibodies against CD71,
TER119 and each of a4, a5 and #1 integrins. Cells were gated into regions as above
and integrin expression within each population was compared. The dark trace rep-
resents integrin expression and the light trace is the background staining of the sec-
ondary antibody alone.
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Figure 2-10: a4, a5 and #1 integrin expression is downregulated during ery-
throid differentiation. Quantification of the data presented in Figure 2-9. Mean
fluoresence values were determined and normalized to the R1+R2 population.
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Figure 2-11: a4, a 5 and 31 integrin message level is downregulated during
erythroid differentiation. Quantitative PCR was used to assess integrin expression
levels in populations of sequentially differentiated erythroid cells. Early progenitor
cells have high level of integrin message while differentiated cells have much lower
levels.
flow cytometry. As shown in Figure 2-12, only the R1+R2 and R3 populations have
significant VCAM-binding ability, indicating that the high a401 integrin expression
levels seen in these cells in Figure 2-9 corresponds to the active conformation.
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Figure 2-12: R1+2 and R3 populations have significant VCAM-1-binding
ability. Sorted R1+2-R5 populations were incubated with increasing concentra-
tions of soluble VCAM-1 in the presence of Mn2+. Unbound VCAM-1 was removed
by washing and cells were stained with a fluourescently labeled VCAM-1 antibody.
VCAM-1 binding was quantitated by flow cytometry. Background binding of VCAM-
1 in presence of EDTA was subtracted from each datum. VCAM-1 binding ability
indicates expression of the active conformation of a401 integrin.
2.4.3 Adhesion of erythroid progenitors
In order to test the functional role of loss of integrin expression on fetal liver erythroid
cells, I adapted a quantitative cell-ECM adhesion assay for use with the fetal liver
erythroid system (Appendix A). A centrifugation assay is ideal for this application
because it is highly quantitative and repeatable while requiring no special equipment
[25]. Using this assay, I demonstrated a progressive loss in adhesion to fibronectin
during erythroid development (Figure 2-13). Sorted R1 to R5 cells were allowed to
attach to plates coated with 10 pg/ml or 3 Ag/ml human plasma fibronectin and then
centrifuged at an acceleration of approximately 1000g. Whereas 75% of R1+R2 cells
adhere to 10 pg/ml fibronectin under these conditions, the fraction of adherent cells
decreases progressively in the R3 to R5 populations. Adhesion of all cell populations
was greater on 10 pg/ml fibronectin than on 3 pg/ml. The progressive decrease in
adhesion on fibronectin parallels the loss of a4, a5 and #1 integrin expression shown
in Figure 2-9.
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Figure 2-13: Adhesion to fibronectin is correlated with integrin receptor
expression. Adhesion of R1+2, R3, R4 and R5 cells to either 10 pig/ml (left) or 3
ig/ml (right) human plasma fibronectin at an acceleration of approximately 1000g.
Cells from each population were sorted and allowed to adhere to fibronectin-coated
plates for 30 minutes before the adhesion assay. Adhesion to fibronectin decreases as
cells differentiate. Asterisks indicate statistical significance at the level of p<0.01.
In order to test the role of specific integrin subunits in mediating adhesion to
fibronectin, I used recombinant fibronectin fusion proteins obtained from Mariette
Vogelezang, a collaborator in the Hynes lab. These recombinant proteins contain
either the a4,31 binding site (VRGD-), the a501 binding site (Vo) or both binding
sites (V) (Figure 2-14).
Cell adhesion assays were performed as above. As shown in Figure 2-15, adhesion
to all fragments mirrors that on fibronectin, in that the fraction of adherent cells on
V, Vo and VRGD- decreases progressively in R1+R2, R3, R4 and R5 populations.
For all populations of cells, adhesion was greatest to the V fragment, which contains
both a 4,31 and a501 integrin binding sites.
I then repeated the adhesion assay with the addition of function-blocking anti-
bodies. Sorted R1+R2 cells were incubated with antibodies to a 4 or a5 integrin
before being added to pre-coated plates. When a4 integrins were blocked on R1+R2
cells, adhesion to the a4,31-binding fragment VRGD- was almost completely abro-
gated, while adhesion to the a 5f 1-binding fragment Vo was unaffected (Figure 2-16).
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Figure 2-14: Schematic diagram of recombinant fibronectin fusion proteins.
The V fragment presents both integrin binding sites. Vo presents just the a5,31 inte-
grin binding site and VRGD- presents just the a401 integrin binding site. VoRGD-
presents neither major integrin binding site. Figure adapted from Mariette Vo-
gelezang.
Figure 2-15: Characterization of erythroid cell adhesion to V, Vo or VRGD
substrates. R1+2, R3, R4 and R5 cells were sorted and adhesion to 10 pg/ml
substrates at an acceleration of ~.1000g was measured. Adhesion on the V fragment
is similar to that on intact fibronectin. Adhesion of all populations was slightly greater
on VRGD- than on Vo, while adhesion to V was the highest.
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Similarly, blocking a5 integrins on R1+R2 cells had no effect on cell adhesion to a 401-
binding fragments but abrogated adhesion to a5/31-binding fragments. These results
indicate that a 431 and a501 integrins on fetal liver erythroid progenitor cells mediate
adhesion to distinct sequences on fibronectin.
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Figure 2-16: a4,31 and a5 ,31 integrins mediate adhesion to different fibronectin
domains. Adhesion of sorted R1+2 cells to 10 pg/ml recombinant fibronectin frag-
ments Vo or VRGD- with and without pre-treatment with function-blocking antibod-
ies to a4 and a5 integrins. Two asterisks indicate statistical significance at the level
of p0.01 and one asterisk indicates statistical significance at the level of p<0.05.
Changes in the levels of integrin expression and corresponding adhesion to fi-
bronectin is physiologically relevant, as erythroid progenitors and erythroblasts must
be retained in the bone marrow or fetal liver whereas the more differentiated reticulo-
cytes must be released into the circulation. Since fibronectin is a major extracellular
matrix protein in both the fetal liver and the bone marrow, I conclude that adhesion
of erythroid progenitors by both a 4 31 and a5,31 integrins is crucial in retaining im-
mature erythroid cells in the marrow, and loss of these integrins likely is crucial in
triggering their release.
2.4.4 Role in two-stage model for erythroid expansion
I were interested to determine if both a 40 1 and a5 ,31 integrins were responsible for
the observed proliferative effects of fibronectin in the second phase of erythropoiesis.
To this end, I cultured TER119- erythroid progenitors on the various recombinant fi-
bronectin fragments in Epo-containing media for one day and then in Epo-free media
for a second day. Importantly, only those cultured on a 4 1-binding substrates V and
VRGD- underwent a dramatic expansion between Day 1 and Day 2 similar to cells cul-
tured on intact fibronectin (Figure 2-17). In contrast, cells cultured on a5 31-binding
fragment Vo exhibited a defect in cell expansion, indicating a 4 1-mediated adhesion
to fibronectin is necessary for maximum numbers of terminal erythroid divisions.
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Figure 2-17: a4 31-rmediated adhesion is required for expansion of differenti-
ating fetal liver erythroid cells. TER119- fetal liver erythroid progenitor cells
were cultured on V, Vo, VRGD-, or VoRGD- substrates with Epo-containing media
for one day and then in Epo-free media for a second day. Only a 4#-binding sub-
strates V and VRGD support an expansion in cell number similar to that seen on
intact fibronectin.
I obtained the same result when I blocked integrin engagement with antibodies.
TER119+ cells were isolated from fetal liver and incubated with function blocking
antibodies against a 4 or a 5 integrins for 15 minutes on ice. Cells were then added
to fibronectin-coated or control plates in Epo-free media. As shown in Figure 2-
18, blocking a4 integrin blocked expansion significantly on fibronectin. Blocking a5
integrin had a lesser effect that was not statistically significant.
Our two-phase model of erythroid expansion predicts that a 4 31 integrin engage-
ment is only necessary during the second, Epo-independent phase. I tested this
prediction by varying the extracellular matrix cues presented to the cells during the
Figure 2-18: Blocking a 4 integrin function blocks cellular expansion.
TER119+ cells were isolated and incubated with function-blocking antibodies to ei-
ther a4 or a5 integrin and then cultured on fibronectin-coated or control substrates
for one day. Average normalized increase in cell number from three experiments are
shown. Asterisks indicate significance at the level of p<0.05.
first and second phases of culture. As seen in Figure 2-19, cells cultured on the a5 1-
binding substrate Vo for the first day exhibit normal expansion when transferred
to a 4#1-binding substrates (FN, VRGD-) for the second day. Conversely, there is
a marked defect in expansion if cells are cultured in the absence of a40 1-mediated
adhesion on the second day, even if a4 0 1 integrin is engaged during the first day of
culture (Figure 2-20). Taken together, these results indicate that the proliferative
effect of fibronectin in the second day of erythropoiesis is a40 1 integrin-dependent.
2.5 Discussion
In this chapter I present data to establish a two-phase model for erythroid expan-
sion. In this model, erythroid progenitor cell expansion is temporally regulated by
the canonical erythropoietic growth factor Epo and the extracellular matrix protein
fibronectin. Using an in vitro model of fetal erythropoiesis, I present evidence that
erythroid progenitor cell expansion is proceeds in two distinct phases, the first gov-
erned by binding of Epo to its receptor and the second by engagement of a 4,l 1 integrin
by fibronectin.
Figure 2-19: Expansion of erythroid progenitors during the second day oc-
curs only in conditions where a40 1 is engaged. TER119- cells were cultured
on Vo substrates in Epo-containing media for the first day and then dissociated and
transferred to wells coated with each of the various integrin-binding substrates in
Epo-free media for a second day.
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Figure 2-20: Expansion of erythroid progenitors during the second day oc-
curs only in conditions where a 4#1 is engaged. TER119- cells were cultured
on VRGD- substrates in Epo-containing media for the first day and then dissociated
and transferred to wells coated with each of the various integrin-binding substrates
in Epo-free media for a second day.
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Erythropoietin and its specific receptor are crucial for promoting the survival, ex-
pansion, and differentiation of mammalian erythroid progenitors [62]. The first stage
of erythroid differentiation, from CFU-E to late basophilic erythroblast, is highly
Epo-dependent, whereas differentiation beyond this stage is no longer dependent on
Epo [39]. Consistent with this, Epo receptors are lost as erythroid progenitors un-
dergo terminal expansion and differentiation [94]. In the culture system for primary
fetal liver erythroid progenitors, Epo is required only during the first day, when the
progenitors undergo the initial ~ 2 divisions, and is not essential for the later stages
of terminal cell expansion and differentiation. This raises the question of what extra-
cellular signals, if any, these differentiating erythroblasts require to support terminal
expansion, differentiation, and enucleation.
Although fibronectin is known to be the major extracellular matrix protein in the
erythroid niche, its role in erythropoietic differentiation and survival was unknown.
I used the established in vitro model of fetal erythropoiesis to systematically vary
the extracellular matrix and growth factor cues presented to erythroid progenitors.
My experiments indicate that withdrawal of Epo during the first day of the culture
period leads to defects in cell expansion. In contrast, the presence or absence of
Epo in the second day of culture had no effect on the extent of expansion of these
more differentiated erythroid cells. Fibronectin plays a reciprocal role in that it has
no effect on the expansion of early erythroid CFU-E progenitors but its absence on
the second day of culture leads to a defect in expansion. These results establish
that erythropoiesis is governed by an early Epo-dependent phase followed by a later
fibronectin-dependent phase.
To determine the molecular mediator(s) of the observed fibronectin response, I
measured integrin expression levels in erythroid progenitor cells; on these cells a4,
a5, and #1 were the mostly highly expressed integrins. Furthermore, I showed a
progressive downregulation of a4, a5 , and #1 integrins over the three-day course of
erythroid differentiation. A quantitative adhesion assay indicated that loss of integrin
expression is correlated with loss of adhesion to fibronectin. Changes in the levels
of integrin expression and corresponding adhesion to fibronectin is physiologically
relevant, as erythroid progenitors and erythroblasts must be retained in the bone
marrow or fetal liver while the more differentiated reticulocytes must be released into
the circulation. In this respect, a 4 and a5 integrins play a similar role in that they
both function as adhesion receptors. Since fibronectin is a major extracellular matrix
protein in the bone marrow, I conclude that adhesion of erythroid progenitors by
both a 4 0 1 and a5 ,31 integrins is crucial in retaining immature erythroid cells in the
marrow, and loss of these integrins likely is crucial in triggering their release.
By culturing erythroid progenitor cells on recombinant fibronectin fragments I
demonstrated that only a 4 #1 integrin engagement supports expansion on fibronectin-
coated surfaces, indicating that a 4 integrins play an additional role in transducing
signals from the extracellular matrix. Previous studies had identified a 40 1 and a501
as the predominant integrins on erythroid progenitors [65], but here for the first time
I distinguish between the roles of these two fibronectin receptors on erythroid cells.
As predicted by the two-phase model, a401 integrin engagement is necessary only
during the second phase of erythropoiesis, when erythroblasts undergo the final ~
2 cell divisions and enucleate. As shown in Figures 2-19 and 2-20, robust cell ex-
pansion is observed when a401 integrin engagement is provided in the second, Epo-
independent phase of the culture period, regardless of whether fibronectin or any of
its fragments was present during the first, Epo-dependent phase. This work thus sug-
gests that a 4 #1 integrin plays two roles in erythroid development. In the first phase
of development, a 4#1 seems to function solely as an adhesion receptor for fibronectin,
while in the second phase it functions to activate pathways necessary for erythroid
expansion.
In other systems cytokine and integrin-mediated signals interact to direct cell
behavior. For example, differentiation of mammary epithelia requires signals initi-
ated by binding of prolactin to its receptor as well as simultaneous engagement of
31 integrins by the basement membrane protein laminin [73]. Similar coordination is
evident in neurogenesis, where simultaneous signals from FGF and 31 integrins are
necessary for neural stem cell maintenance and expansion [10]. One important dis-
tinction of these developmental pathways with erythroid development is that growth
factor and integrin-mediated signals regulate erythroid cells at very different stages
of differentiation whereas in these other systems they occur simultaneously.
The observed temporal separation in growth factor-mediated and integrin-mediated
signaling can be thought of as both a consequence of the dramatic morphological and
biochemical changes that take place during erythropoiesis as well as perhaps an indi-
cation. Microarray analysis of fetal liver erythroid cells at sequentially differentiated
stages revealed that the most dramatic changes in the set of differentially expressed
genes occurs between R2 and R3 cells (Hattangadi, Young and Lodish, unpublished
data). Such genome-wide analysis provides further support for the two-stage model
by indicating that early and late erythroid cells are in fact very different.
Integrin-mediated adhesion to the extracellular matrix initiates a diverse set of
intracellular signaling pathways specific to each integrin dimer and cell type. Little is
known about the precise downstream pathways activated following integrin receptor-
ligand binding in erythroid cells. Exploring the signals that emanate from a401
integrins in response to fibronectin binding and how these signals interact with those
downstream of the Epo receptor is discussed in Chapter 3.
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Chapter 3
Integrin Signaling in
Erythropoiesis
3.1 Introduction
As presented in Chapter 2, integrin expression on fetal liver erythroid progenitor cells
has a functional role in adhesion to extracellular matrix proteins as well as biological
significance in supporting terminal erythroid expansion. In this chapter, I present
my work investigating the mechanisms by which integrins mediate this behavior. In
particular, I show that integrins promote survival of differentiating erythroid cells in
the second phase of erythropoiesis by upregulation of the anti-apoptotic protein bcl-xl,
much like the action of erythropoietin on immature erythroid progenitors in the first
phase. In addition, I show that integrins are dispensable for erythroid differentiation,
providing evidence to decouple these pathways. Finally, I show activation of canonical
integrin signaling pathways downstream of fibronectin binding.
3.2 Cell cycle analysis
As seen in Figure 2-17, a401 integrin engagement is necessary for expansion of ery-
throid cells. The total number of cells in a culture can increase over time by two
mechanisms. One is an increase in cellular proliferation; the other is a decrease in
cell death. To explore the mechanism of a4,31 integrin-mediated support of cellular
expansion, I first tested the hypothesis that a 4 0 1 integrin engagement promotes entry
into the cell cycle. First, TER119- cells were isolated from fetal liver and cultured on
fibronectin or control substrate in the presence of Epo for one day. Cell cycle status
was assessed using BrdU and PI staining. As shown in Table 3.1, the presence or
absence of fibronectin in the first day had no effect of the percentage of cells in each
stage of the cell cycle. However, withdrawal of Epo during this time had the effect of
decreasing the percentage of cells in S phase.
Table 3.1: Cell cycle analysis of the first day of erythropoiesis
Go/Gi G2/M S
Time 0 51.4% 5.7% 42.3%
Day 1 FN 46.3% 4.3% 49.5%
Day 1 PBS 38.9% 8.1% 53.0%
Day 1 FN-Epo 52.0% 6.7% 41.3%
To test the cell cycle status of cells in the second phase of erythropoiesis, I isolated
TER119+ cells and cultured them without Epo on fibronectin or its various fragments.
Cell cycle status was assessed at four hour time points. On fibronectin, the vast
majority cells transitioned to Go/G1 over the 24 hour culture. As shown in Table
3.2, this pattern was generally the same on all substrates, including the uncoated
control, indicating that the presence or absence of integrin engagement has no direct
effect on cell cycle status. Furthermore, the use of an intracellular fluorescent dye
to track cell division also showed no difference in the proliferative potential of cell
cultured on different integrin-engaging substrates (data not shown). Thus the other
remaining explanation for the cellular expansion seen in the presence of a 4 0 1 integrin
engagement was that rather than promote expansion of erythroid cells directly via
cell cycle entry, a401 integrins prevent cell death.
Table 3.2: Cell cycle analysis of the second day of erythropoiesis
Go/G1 G2/M S
Time 0 44.5% 8.8% 46.7%
4h FN 54.4% 11.2% 34.3%
4h Vo 55.0% 11.8% 33.2%
4h VRGD 60.7% 6.9% 32.4%
4h PBS 53.2% 8.4% 38.4%
8h FN 65.6% 12.7% 21.8%
8h Vo 72.3% 11.6% 16.1%
8h VRGD 80.2% 6.7% 13.1%
8h PBS 65.0% 15.9% 19.1%
Day 1 FN 84.2% 4.1% 11.7%
Day 1 Vo 88.2% 3.3% 8.6%
Day 1 VRGD 90.6% 3.6% 5.8%
Day 1 PBS 89.0% 3.0% 8.0%
3.3 Integrin-mediated protection from apoptosis
3.3.1 Background
Apoptosis is a coordinated process of cell death by which excess cells are removed
during development and growth. Distinct from necrosis, in which a cell dies due to
acute injury, apoptosis, Greek for falling away, is a methodical, step-wise process
where critical signaling proteins are digested, the nuclear membrane is disrupted and
eventually the cell breaks apart into small fragments with are then phagocytosed.
This process is orchestrated by a network of proteins referred to as the apoptosome,
in which a series of initiator and executor proteins stimulate a cascade of competing
pro- and anti-apoptotic signals [60, 63].
The role of Epo in preventing apoptosis of erythroid progenitors is well docu-
mented. Previous work in the Lodish lab established that signaling events down-
stream of the EpoR lead to an upregulation of the anti-apoptotic protein bcl-xl, and
that this pathway is in part mediated by Stat5 [70]. The role of integrins in prevent-
ing apoptosis is also well characterized. In fact, anoikis, Greek for homelessness, is
the specific form of apoptosis that results when cells are detached from the extra-
cellular matrix [19]. In many cases, integrin engagement leads to the generation of
anti-apoptotic signals through the P13-K and Akt pathways [60]. Because I found no
direct effect of integrin engagement on cell cycle status, I investigated the role that
integrins may play in survival of erythroid progenitors.
3.3.2 Annexin V
It is well known that Epo protects early erythroid progenitors from apoptosis [70], so I
tested the hypothesis that fibronectin acts in a similar manner. First, I examined the
roles of Epo and fibronectin in preventing apoptosis of early erythroid progenitors in
the first phase of erythropoiesis using the annexin V binding assay. One of the early
morphological changes during apoptosis is translocation of the plasma membrane
phospholipid phosphatidylserine from the inner to the outer leaflet of the plasma
membrane. When exposed in this manner, phosphatidylserine can bind annexin V,
constituting the principle of the assay. I found that nearly 40% of TER119- cells
cultured overnight on fibronectin in the absence of Epo were annexin V positive
(Figure 3-1). When Epo was present in the culture medium, the percentage of annexin
V positive cells dropped to 23.6%, confirming that Epo plays an anti-apoptotic role
during the first phase of erythropoiesis. However, the absence of fibronectin, either
in the presence or absence of Epo, did not have an effect on the level of apoptosis
(Figure 3-1).
To test the role of Epo and fibronectin in preventing apoptosis during the second
phase of erythropoiesis, TER119~ progenitors were cultured overnight on uncoated
substrates with Epo as above and then transferred to fresh fibronectin or control
substrates in the absence of Epo. Four hours post Epo removal, 28.8% of the cells
from PBS wells were annexin V positive, versus 17.1% of those on fibronectin (Figure
3-2), indicating that the presence of fibronectin during the second phase partially
protects erythroid cells from apoptotic death.
I went on characterize the role of a4#1 integrin in preventing apoptosis of dif-
ferentiating erythroid cells. TER119- progenitor cells were cultured overnight on
uncoated substrates in the presence of Epo and then transferred to fresh fibronectin
Figure 3-1: Epo and fibronectin protect against apoptosis. TER119- progeni-
tor cells were cultured overnight on fibronectin or uncoated substrates in the presence
or absence of Epo. AnnexinV binding (shown on the y-axis) was assayed via flow cy-
tometry and the percentage of positive cells is indicated on each plot. The absence of
Epo during the first day of culture leads to an increase the percentage of apoptotic
cells, but the absence of fibronectin does not have an effect.
or uncoated wells in the presence or absence of function-blocking antibodies to a4
and a5 integrin. Blocking a 4 integrin increased the percentage of annexin V posi-
tive cells four hours post Epo removal whereas blocking a5 integrin had little effect
(Figure 3-2). Representative flow cytometry data are shown in Figure 3-2 and the
normalized averages of 3 independent experiments are shown in Figure 3-3. Taken
together, these results establish that a 4 0 1 integrin protects differentiating erythroid
cells from apoptosis much like the action of Epo on early erythroid progenitors.
3.3.3 Bcl-xL
Bcl family proteins regulate apoptosis by either inducing or inhibiting the release
of cytochrome c from the mitochondria into the cytosol. One of the mechanisms of
apoptosis protection mediated by Epo is through upregulation of the anti-apoptotic
protein bcl-xL [70], so I tested whether fibronectin protects against apoptosis in a
similar manner in the second phase of erythropoesis. TER119- progenitors were
cultured overnight on uncoated substrates in the presence of Epo and then serum-
starved for one hour before being transferred to fresh fibronectin or control substrates
in the absence of Epo as above. Cells were lysed at 5, 15 and 30 minutes and bcl-xL
protein expression was assessed via Western blot. As shown in the representative
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Figure 3-2: Fibronectin protects from apoptosis in the second stage of ex-
pansion through a401 integrin. TER119- fetal liver cells were purified and cul-
tured overnight on uncoated substrates in Epo-containing media. Cells were then
dissociated, incubated with or without antibodies to a 4 or a5 integrins and cultured
in Epo-free media on fibronectin or control substrates. Four hours post-Epo removal,
the cells were stained with annexin V (y-axis) and 7-AAD (x-axis) to assay for apop-
tosis. Data are representative of three independent experiments.
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Figure 3-3: Summary of apoptosis data. The percentage of annexin V positive
cells was normalized to that on fibronectin. Treatment with a function-blocking
antibody to a4 integrin significantly increases the percentage of apoptotic cells four
hours post-Epo removal, while blocking a5 integrin has no effect. Two asterisks
indicate statistical significance at the level of p< 0.01 and one asterisk indicates
statistical significance at the level of p< 0.05.
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Western blot below (Figure 3-4), expression is distinctly higher in cells cultured on
fibronectin than those cultured on control substrates. The Western blot in Figure 3-5
shows bcl-xl expression at 30 minutes in addition to a loading control, as represented
by equivalent expression of an actin. Summary of these data are presented in Figure
3-6.
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Figure 3-4: Representative Western blot of bcl-xL protein expression.
TER119- progenitors were cultured overnight on uncoated substrates in the pres-
ence of Epo and then serum-starved for one hour before being transferred to fresh
fibronectin or control substrates in the absence of Epo. Bcl-xL expression is distinctly
higher in cells cultured on fibronectin than those cultured on control substrates.
FN PBS
actin 45 kDa
bcl-xl 30 kDa
Figure 3-5: Representative Western blot of bcl-xL protein expression with
loading control. Bel-xL expression was assessed 30 minutes post-Epo removal. Bcl-
xl expression distinctly higher in cells cultured on FN than those cultured on control
substrates, whereas expression of actin is equivalent.
Treating cells with function-blocking antibodies to a4 and a 5 integrins provided
a means of analyzing the contribution of these molecules to bcl-xL upregulation.
TER119- progenitors were cultured overnight on uncoated substrates in the presence
of Epo and then serum-starved for one hour before being incubated with antibodies
to a 4 or a5 integrin. Cells were then transferred to fibronectin-coated wells in the
absence of Epo. Blocking a 4 integrin resulted in abrogation of bcl-xl upregulation,
while blocking a5 integrin had a smaller effect (Figure 3-7). These data confirm the
anti-apoptotic role of a 4 integrin in the second phase of erythropoiesis.
Figure 3-6: Summary of bcl-xL Western blot data. The ratio of bcl-xL expres-
sion on fibronectin to that on a control substrate at 30 minutes in four independent
experiments were averaged. Asterisk indicates significance at the level of p<0.05.
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Figure 3-7: a4 integrin mediates bcl-xl upregulation. TER119- progenitors were
cultured overnight on uncoated substrates in the presence of Epo and then serum-
starved for one hour before being incubated with antibodies to a4 or a5 integrin.
Cells were then transferred to fibronectin-coated wells in the absence of Epo. Bcl-xL
expression was assessed 30 minutes post-Epo removal via Western blot. Each bar is
the average ratio of bcl-xl expression to GAPDH expression in two experiments.
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Similar results were obtained via flow cytometry (Figure 3-8). One hour after Epo
withdrawal, cells were fixed, permeabilized and stained with an antibody to bcl-xL.
Bcl-xL expression in cells cultured on fibronectin was higher than those cultured on
control substrates.
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Figure 3-8: Flow cytometric analysis of bcl-xL expression. TER119- progeni-
tors were cultured overnight on uncoated substrates in the presence of Epo and then
transferred to fibronectin-coated or control substrates in the absence of Epo. One
hour after Epo withdrawal, bcl-xL expression is distinctly higher in cells cultured
on fibronectin (black trace) than those cultured on control substrates (grey trace).
Background staining (filled histogram) was determined by staining of the secondary
antibody alone.
Further confirmation of this effect came from quantitative PCR data (Figure 3-9).
Cells were cultured as above overnight in the presence or absence of Epo. Total RNA
was isolated, reverse transcribed and amplified using specific primers. As shown in
the left side of Figure 3-9, the presence of Epo in the first phase of culture leads
to upregulation of bcl-xL. Cells that were cultured with Epo overnight were then
cultured in Epo-free media on fibronectin or control substrates. Total RNA was
isolated at 15 minutes, one hour and four hour time points and reverse transcribed
and amplified as above. At each time point, bcl-xL expression on fibronectin was
normalized to expression of the 18S ribosomal subunit as well as to expression on
the control substrate. As seen in Figure 3-9, relative expression of bcl-xL steadily
increased during culture on fibronectin, indicating that the presence of fibronectin in
the second phase promotes cell survival much like the presence of Epo in the first
phase.
Figure 3-9: Quantitative PCR analysis of bcl-xL expression. To measure bcl-
xl expression in the first phase of erythropoiesis (left side), TER119- progenitors
were cultured overnight on uncoated substrates in the presence or absence of Epo
overnight and bcl-xl expression was measured by Western blot. To measure bcl-
xl expression in the second phase (right side), TER119- progenitors were cultured
overnight on uncoated substrates in the presence of Epo overnight and then trans-
ferred to fibronectin-coated or control substrates in the absence of Epo. The presence
of fibronectin in the second phase upregulates the anti-apoptotic protein bcl-xL much
like the presence of Epo in the first phase.
3.3.4 Caspase-3
In order to show that integrins provide protection from apoptosis, I was interested to
assay apoptotic proteins at a various stages in the pathway. Caspases are the executor
proteins of apoptosis; in their active forms they enzymatically cleave a variety of
cellular substrates. Caspase-3 is a key component of the caspase cascade in that in
its active form it not only cleaves target proteins but also cleaves its own regulator,
caspase-9, forming a positive feedback loop [60].
I used flow cytometry to measure the level of cleaved (active) caspase-3. TER119-
cells were cultured overnight with Epo and then transferred to fibronectin or control
substrates in Epo-free media. At the indicated time points, cells were dissociated,
fixed and permeabilized in order to stain with an intracellular antibody specific to
cleaved caspase-3. As shown in Figure 3-10, cells cultured in the absence of fibronectin
indicate a higher level of active caspase-3 expression, indicating a higher level of
apoptosis. Again, these data add evidence to the model that integrin engagement in
the second phase of erythropoiesis leads to increased cell survival.
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Figure 3-10: Flow cytometry analysis of cleaved caspase-3 expression.
TER119- cells were cultured overnight with Epo and then transferred to fibronectin
or control substrates in Epo-free media. At the indicated time points, cells were
fixed and permeabilized and stained with an intracellular antibody specific to cleaved
caspase-3. The absence of fibronectin in the second phase activates the pro-apoptotic
protein caspase-3. In each plot, the dark-filled histogram represents the expression
level in the absence of fibronectin, the medium-filled histogram the expression level
in the presence of fibronectin, and the unfilled histogram the secondary antibody
control.
3.4 Role in differentiation
Integrins play an important role in differentiation of many different cell types. For ex-
ample, differentiation of mammary epithelia is dependent upon 31 integrin-mediated
adhesion to the extracellular matrix protein laminin [73] and fibronectin inhibits ter-
minal differentiation of keratinoyctes via integrins as well [3]. Given the observed
effects of a 4,31 integrin on erythroid cell expansion, I tested whether a 4,31 integrins
had any effect on erythroid differentiation.
As shown in Figure 2-2, our fetal erythroid culture system is well suited to tracking
differentiation in vitro using the cell surface markers CD71 and TER119. To test the
role of integrins in erythroid differentiation, TER119- cells were isolated and cultured
on fibronectin and its fragments in the presence of Epo for 16-18 hours. After this
time, the media was changed to Epo-free media and the culture was carried out for two
more days. At each time point, cells were dissociated and stained with antibodies
to CD71 and TER119 to assess the level of differentiation via flow cytometry. As
shown in Figure 3-11, the pattern of CD71 upregulation, TER119 upregulation and
subsequent CD71 downregulation is unchanged in the absence of fibronectin or a401
integrin engagment. When Epo was absent from the culture media for the first
phase, as shown in the right-most column in Figure 3-11, there is a significant defect
in upregulation of CD71 during the first day. As previously suggested by Arroyo et
al, these data provide direct evidence to decouple the pathways controlling erythroid
differentiation and survival, in that cell survival is mediated by a401 integrin, while
differentiation is a401 integrin-independent.
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Figure 3-11: Role of integrins in erythroid differentiation. TER119- cells
were isolated and cultured on fibronectin and its various fragments and CD71 and
TER119 expression was analyzed using flow cytometry. The presence or absence of
a431 integrin engagement had no effect on erythroid differentiation, as indicated by
similar staining patterns for cells cultured on Vo, VRGD- and PBS as on FN and V.
Only in the absence of Epo (right-most column) is there a defect in differentiation.
3.5 Focal adhesion signaling
3.5.1 Paxillin and Pyk2
Formation of focal adhesions is one of the hallmarks of integrin signaling. These
protein complexes are often centered around focal adhesion kinase (FAK), which forms
linkages to cytoskeletal components in addition to activating downstream signaling
pathways [87]. However, as suggested by others, I found that the closely related family
member proline-rich tyrosine kinase-2 (Pyk2) rather than FAK itself is expressed in
hematopoietic cells [5]. FAK and Pyk2 have 48% amino acid identity and share the
same domain structure: a unique N-terminus, a protein tyrosine kinase domain, and
two proline-rich regions at the C-terminus [5]. Quantitative real time PCR indicated
expression of Pyk2 to be at least 3-fold greater than that of FAK in freshly isolated
TER119- over four orders of magnitude input RNA amount (Figure 3-12).
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Figure 3-12: Expression of Pyk2 and FAK in TER119- cells. Quantitative PCR
was used to assess Pyk2 and FAK expression in freshly isolated TERI 19-. Expression
of Pyk2 was at least 3-fold greater than that of FAK over four orders of magnitude
input RNA amount. Data were normalized to expression of 18S ribosomal RNA as
well as to FAK expression at each input RNA amount.
To assay Pyk2 activation, TER119- were isolated and cultured overnight in the
presence of Epo. Cells were serum-starved for one hour and then transferred to
fibronectin-coated or control wells in the absence of Epo. Cells were lysed at the
indicated times and proteins were analyzed via Western blot. Membranes were blot-
ted with anti-phosphoPyk2 antibody as well as anti-GAPDH antibody as a loading
control. As shown in Figure 3-13 Pyk2 phosphorylation increases with time in cells
cultured on fibronectin, but less so on control substrates, indicating that the presence
of fibronectin activates Pyk2. Quantitation and summary of these data in are shown
in Figure 3-14).
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Figure 3-13: Representative time course of Pyk2 phosphorylation in re-
sponse to fibronectin. TER119- cells were cultured overnight in the presence
of Epo and then serum-starved for one hour and transferred to fibronectin-coated
or control wells. Pyk2 activation was analyzed by Western blot with GAPDH as a
control. The presence of fibronectin leads to Pyk2 activation.
Figure 3-14: Quantification of Pyk2 phosphorylation time course. Each bar
represents the average of the ratio of phosphorylated Pyk2 to GAPDH normalized
to that on fibronectin at 5 minutes in two experiments. The presence of fibronectin
leads to Pyk2 activation.
Blocking a4 integrin interaction with fibronectin blocked Pyk2 activation (Figure
3-15). TER119- were isolated and cultured overnight in the presence of Epo. Cells
were serum-starved for one hour and then incubated with function-blocking antibodies
to a4 or a5 integrin and then transferred to fibronectin-coated or control wells in the
absence of Epo. Cells were lysed after 30 minutes and lysates were analyzed via
Western blot. Membranes were blotted with anti-phosphoPyk2 antibody as well as
anti-GAPDH antibody as a loading control. The ratio of phosphorylated Pyk2 to
GAPDH is dramatically decreased when a 4 integrin binding to fibronectin is blocked
while blocking a5 integrin has little effect. These data indicate that activation of
Pyk2 in the second phase of erythropoiesis is mediated by fibronectin binding to a 4
integrin.
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Figure 3-15: Pyk2 activation is mediated by a4 integrin. TER119- cells were
cultured overnight in the presence of Epo and then serum-starved for one hour and
incubated with function-blocking antibodies to a4 or a5 integrin and then transferred
to fibronectin-coated or control wells. Pyk2 activation was analyzed by Western blot.
Each bar represents the average of the ratio of phosphorylated Pyk2 to GAPDH nor-
malized to that on fibronectin in two experiments. Two asterisks indicate statistical
significance at the level of p<0.001 and one asterisk indicates statistical significance
at the level of p<0.05.
One of the roles of Pyk2 is to phosphorylate paxillin, a small adaptor protein that
directly associates with the cytoplasmic tail of a 4 integrin [79]. Paxillin, through its
numerous protein-binding domains, interacts with a variety of signaling molecules,
thereby transmitting integrin-generated signals to the interior of the cell. One impor-
tant biological consequence of a 4 integrin interaction with paxillin is the inhibition
of cell spreading and migration [42].
An IP-Western approach was used to determine the role of paxillin in the integrin-
dependent phase of erythropoiesis. TER119- were isolated and cultured overnight
in the presence of Epo. Cells were serum-starved for one hour and then transferred
to fibronectin-coated or control wells in the absence of Epo. Cells were lysed and
paxillin was immunoprecipitated from the lysates. Resulting proteins were analyzed
via Western blot with anti-phosphopaxillin and anti-paxillin antibodies. As shown in
Figure 3-16, phosphorylation of paxillin proceeds in a biphasic fashion (Figure 3-16).
The data at 30 minutes were normalized and averaged, showing a significant decrease
in the ratio of phosphorylated paxillin to total paxillin on control substrates relative
to fibronectin (Figure 3-17). Taken together, these data establish that paxillin is
activated in the presence of fibronectin in the second phase of erythropoiesis.
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Figure 3-16: Representative time course of paxillin activation. TER119- cells
were cultured overnight in the presence of Epo and then serum-starved for one hour
and transferred to fibronectin-coated or control wells. Paxillin activation was ana-
lyzed using an IP-Western approach. Each bar represents the ratio of phosphorylated
paxillin to total paxillin normalized to that on fibronectin at 5 minutes. The presence
of fibronectin leads to biphasic paxillin activation.
Pyk2 and paxillin have also been shown to have a direct physical interaction
[33]. In the second phase of erythropoiesis, the presence of fibronectin also stim-
ulates binding of paxillin and Pyk2 (Figure 3-18). TER119- cells were cultured
overnight in the presence of Epo and then serum-starved for one hour and trans-
ferred to fibronectin-coated or control wells. Paxillin was immunoprecipitated and
proteins were analyzed via Western blot. As shown in Figure 3-18, phosphorylated
Pyk2 co-immunoprecipitated with paxillin. Qualitatively, the level of phosphorylated
Figure 3-17: Activation of paxillin in the second phase of erythropoiesis.
TER119- cells were cultured overnight in the presence of Epo and then serum-starved
for one hour and transferred to fibronectin-coated or control wells. Paxillin activa-
tion was analyzed using an IP-Western approach. The ratio of phosphorylated pax-
illin to total paxillin at 30 minutes on control substrates was normalized to that on
fibronectin. The presence of fibronectin leads to a significant increase in paxillin
activation. Asterisks represent statistical significance at the level of p <0.001.
Pyk2 and phosphorylated paxillin was greater in the presence of fibronectin than on
control substrates. Taken together with the data presented above, a model where
fibronectin binding to a 4 0 1 integrin activates paxillin and Pyk2 and also stimulates
their binding can be proposed.
3.5.2 Src-family kinases
I was also interested in exploring activation of Src-family kinases (SFKs) downstream
of a4# 1 integrin in the second phase of eryhropoiesis. Upon integrin activation, some
SFK family members are known to be activated and associated with focal adhesions
[76]. SFKs have also been shown to play roles in the hematopoietic system. Lyn-/-
adult bone marrow cells exhibited defects in production of TER119+ erythroid cells
as well as increased apoptosis and decreased cell cycle entry [31]. Thus I hypothesized
that SFKs may play a role downstream of integrins in erythroid expansion or survival.
I used the Src-family kinase pharmacological inhibitor PP2 to explore the role
of SFKs in erythropoiesis. PP2 inhibits the kinase activity of Src kinase as well as
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Figure 3-18: Co-immunoprecipitation of paxillin and Pyk2. TER119- cells
were cultured overnight in the presence of Epo and then serum-starved for one hour
and transferred to fibronectin-coated or control wells. Paxillin was immunoprecipi-
tated and resulting proteins were analyzed by Western blot. Membranes were first
blotted with phospho-paxillin and phospho-Pyk2 antibodies and stripped and re-
blotted with total paxillin antibody. On fibronectin but not control substrates, phos-
phorylated paxillin and phosphorylated Pyk2 co-immunoprecipitate. These blots are
representative of two experiments.
other family members. TER119+ cells were isolated from fetal liver and treated with
increasing concentrations of PP2, PP3, the inactive analogue, or an equal volume of
DMSO as an added control. Cells were then cultured on fibronectin coated plates
for one day and cell number was assessed. As shown in Figure 3-19, PP2 blocks
fibronectin-dependent expansion of erythroid cells in a dose-dependent manner.
Figure 3-19: Src-family kinase inhibitor PP2 blocks fibronectin-dependent
exansion in a dose-dependent manner. TER119+ cells were treated with PP2, its
inactive analogue PP3 or DMSO as a control and cultured for one day on fibronectin-
coated plates. Each bar represents the average number of cells per well normalized
to that in untreated cells.
The Src family is composed of many closely related family members, so it was
necessary to determine which family members were expressed in fetal liver erythroid
cells. To do so, expression of SFK isoforms was assessed by real time PCR in both
TER119~ and TER119+ cells (Figure 3-20). Hck was found to be highly expressed in
TER119~ cells and Lyn was highly expressed in both TER119- and TER119+ cells.
Thus these two family members so were chosen for further analysis.
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Figure 3-20: Expression of Src-family kinases in fetal liver erythroid cells.
TER119~ and TER119+ cells were isolated and expression of SFKs was assessed
using real time PCR. Hck was highly expressed in TER119- cells and Lyn was highly
expressed in both TER119- and TER119+ cells.
To determine the role of Hck and Lyn in fibronectin-dependent erythroid expan-
sion, I undertook an immunoprecipitation-Western blot approach. TER119- cells
were isolated from fetal liver and cultured overnight in the presence of Epo on un-
coated plates. Cells were then serum-starved in the absence of Epo for one hour
and transferred to fibronectin or uncoated wells. At the indicated time points, cells
were lysed and proteins were analyzed via Western blot. Membranes were blotted
with anti-phosphotyrosine and anti-Hck or anti-Lyn antibodies. As shown below,
there was no significant difference in phosphorylation levels of Hek between treated
(fibronectin) and untreated (PBS) cells (Figure 3-21). Although in the case of Lyn
there was a decrease in relative phosphorylation at 5 minutes (Figure 3-22), the fact
that Lyn kinase is activated by a combination of phosphorylation and dephosphory-
lation events make it difficult to interpret these data.
Figure 3-21: Phosphorylation of Hck kinase during fibronectin-dependent
erythroid expansion. TER119- cells were cultured overnight in the presence of
Epo and then serum-starved for one hour and transferred to fibronectin-coated or
control wells in the absence of Epo. Cells were lysed at the indicated times and
phosphotyrosine and total Hck levels were determined by Western blot. Data are the
normalized averages of three experiments.
Figure 3-22: Phosphorylation of Lyn kinase during fibronectin-dependent
erythroid expansion. TER119- cells were cultured overnight in the presence of
Epo and then serum-starved for one hour and transferred to fibronectin-coated or
control wells in the absence of Epo. Cells were lysed at the indicated times and
phosphotyrosine and total Lyn levels were determined by Western blot. Data are the
normalized averages of three experiments. Asterisk indicates significance at the level
of p< 0.05.
3.6 Discussion
In this chapter I present data on the role of a401 integrin-mediated signals in ery-
thropoiesis. As shown in Chapter 2, a4#1 integrin is necessary and sufficient for
terminal erythroid expansion. The first phase of erythroid expansion is largely gov-
erned by binding of Epo to its receptor. The events downstream of EpoR activation
are well characterized, and include auto-phosphorylation of receptor subunits, phos-
phorylation of JAK2 and STAT5 and subsequent translocation of STAT5 dimers to
the nucleus [62]. Although a 4 0 1 and a5,31 integrins had been identified as impor-
tant in the erythroid niche, virtually nothing about their biological significance or
downstream signaling events was known.
3.6.1 Cellular proliferation and death
One important function of EpoR-mediated signals is to activate anti-apoptotic path-
ways in order to promote survival of erythroid progenitors. This is seen in upreg-
ulation of bcl-xl in the presence of Epo in the first phase of erythropoiesis [70]. In
beginning to explore the mechanism by which a 4 01 integrin supports erythroid cell
expansion, I first tested the hypothesis that a40 1 integrin stimulates cellular prolif-
eration. By analyzing the cell cycle status of cells cultured on various fragments, I
determined that engagement of integrins in the second phase of erythropoiesis has
no direct effect on cellular proliferation. However, the withdrawal of Epo in the first
day of culture reduced the percentage of cells in S phase, indicating a direct effect on
cellular proliferation.
Next, I focused on potential anti-apoptotic effects. While withdrawal of Epo dur-
ing the first day of culture led to an increase in the percentage of apoptotic cells, the
presence or absence of fibronectin during this time had no effect. However, in the
second phase of erythropoiesis fibronectin does play an anti-apoptotic role. Further-
more, this effect is mediated by a4#1 integrin. Blocking a4 integrin led to an increase
in the percentage of apoptotic cells, similar to culturing cells in the absence of fi-
bronectin, while blocking a5 integrin had a minimal effect on the level of apoptosis.
One mechanism of apoptosis protection by fibronectin binding was through upregula-
tion of bcl-xl, much like the effect of Epo on early erythroid progenitors. Blocking a4
integrin engagement with an antibody abrogated this effect. Taken together, these re-
sults establish that one of the roles of fibronectin in the erythroid niche is to protect
differentiating erythroid cells from apoptosis, and that this behavior is specifically
mediated by a401 integrin.
Differentiation, in general, is associated with cell cycle arrest. In erythroid cells,
however, one of the hallmarks of terminal differentiation is an expansion in cell num-
ber. Erythroid cell divisions can categorized into two types. Early erythroid progen-
itors undergo "renewal divisions" where the number of progenitors is doubled while
maintaining differentiation potential. Later, erythroid cell divisions can be termed
"differentiation divisions" where reduction in cell size resulting from cell division is
a necessary step in terminal differentiation. There is evidence to suggest that these
two types of cell divisions are marked by differing cell cycle characteristics as well as
differing regulatory mechanisms [16, 36].
One question that follows from my work is the role that Epo and fibronectin may
play in stimulating these different types of cell divisions. While my data suggests that
integrin engagement in the second phase of erythropoeisis does not stimulate entry
into the cell cycle, it could be that the types of cell divisions - as distinguished by the
length of each phase and as well as activation of specific regulatory molecules - are in
fact determined by integrin engagement.
The finding that integrin engagement does not directly induce cell cycle entry
is important in that it highlights the distinction between cell proliferation and cell
survival. Whereas the data suggest that Epo-mediated signaling directly stimulates
proliferation and as well as survival, a401 integrin seems to have only an anti-apoptotic
role. One issue that is unclear, however, is whether the expansion seen in the second
phase is driven by proliferative signals established by Epo in the first phase that con-
tinue in its absence in the second phase or merely a reduction in apoptosis mediated
by a 4 31 integrins.
3.6.2 Differentiation
Interestingly, I found that integrin engagement is not essential for differentiation
of erythroid progenitors, as measured by expression levels of CD71 and TER119,
supporting the view that erythroid differentiation and expansion are decoupled and
regulated by separate pathways [4]. Withdrawal of Epo during the first phase of
erythropoiesis, and lack of engagement of a401 integrin during the second phase,
both lead to increased apoptosis. Dead cells cannot proliferate or differentiate, and
thus it is difficult to determine whether signals downstream of the EpoR or a401
integrin directly activate signal transduction pathways leading to cell proliferation
or differentiation. Alternatively, by preventing apoptosis these signals could allow
previously inscribed signaling pathways to support both cell division and induction
of erythroid-specific genes.
There appears to be a distinction in the requirement for a431 integrins in fetal
and adult erythropoiesis. While a 4 integrin-null fetal liver progenitors fail to develop
into large colonies in vitro, faint red staining is visible, suggesting that proliferation
but not differentiation is disrupted in the absence of a4 integrin [4]. In an adult
conditional knockout model, there was no reduction in the number of TER119+ cells
in the bone marrow of adult mice induced to lose a 4 integrin expression, but these
animals exhibited an impaired response to anemia, with decreased numbers of reticu-
locytes and red blood cells [68]. This evidence that a 4 integrin is required for terminal
erythroid proliferation during adult stress-induced erythropoiesis is consistent with
my findings and thereby suggests that fetal and stress-induced erythropoiesis may
be regulated differently from adult homeostatic erythropoiesis. Our in vitro model
of fetal erythropoiesis allowed us to make direct, quantitative measurements of ery-
throid expansion and differentiation to show that these processes are in fact regulated
separately.
3.6.3 Focal adhesions
Although the roles of a 4,31 and a5 0 1 integrins in adhesion of erythroid cells has long
been established, very little information about any downstream signaling events was
known. By demonstrating a role for a40 1 in providing protection from apoptosis via
upregulation of bcl-xL, I have established that a 4 0 1 functions as a signaling receptor
in addition to an adhesion receptor. In order to add support to that claim, I charac-
terized some of the signaling events downstream of a 4#1 engagement by fibronectin
in the erythroid niche.
Formation of focal adhesions are in many ways the hallmark of integrin signaling.
Engagement of integrins by ligand binding leads to clustering of receptors on the cell
surface as well as recruitment of signaling molecules in the cytoplasm. Typically,
activation of FAK and other tyrosine kinases lead to activation of various signaling
molecules including MAPK, Rac and P13K. Paxillin is an important adaptor pro-
tein in the midst of this signaling network. Paxillin physically interacts with the
cytoplasmic tail of a 4 integrin, and through its numerous protein binding domains,
binds proteins that directly contribute to reorganization of the actin cytoskeleton
[79]. Through this relationship with the cytoskeleton, integrin activation can result
in formation of stress fibers and influence cell motility.
When initial Western blot experiments looking at FAK expression and activation
in erythroid cells were unsuccessful, I began to focus on Pyk2, a closely related FAK
family member whose expression had been documented in hematopoietic cells [15].
Via quantitative PCR, I determined that expression of Pyk2 is at least 3-fold greater
than that of FAK over several orders of magnitude input RNA in TER119- cells. IP-
Western blot studies indicated a 4 integrin-dependent activation of Pyk2 and paxillin
upon fibronectin binding in the second phase of erythroid culture. In addition, the ac-
tive forms of Pyk2 and paxillin co-immunoprecipitated in the presence of fibronectin.
Although Pyk2 is known to phosphorylate paxillin, it cannot be explicitly be deter-
mined from the experiments presented here if binding precedes paxillin activation or
if binding takes place only between active forms of the proteins. Taken together,
however, these data aid in characterizing the signaling behavior of a 401 integrin in
erythroid cells.
One curious aspect of integrin signaling in erythroid cells is the role of the cy-
toskeleton. Erythroid cells are typically considered to be suspension cells in that they
do not spread on tissue culture plastic or other substrates. Indeed, in my many ad-
hesion experiments, I never observed any spread cells despite populations of strongly
adherent cells. Paxillin is the key to this behavior. Binding of paxillin to the a4 cyto-
plasmic tail inhibits cell spreading, as well as focal adhesion and stress fiber formation
[42]. The biological significance of this behavior is that at the integrin-dependent stage
of erythropoiesis, differentiating erythroid cells are preparing to leave the erythroid
niche and enter the blood stream, and thus spreading on an extracellular matrix pro-
tein would be counterproductive. In addition, in other cell types a point mutation
that distrupted integrin-paxillin binding markedly decreased cell migration [42, 64].
Further investigation of this mechanism in erythroid cells is needed, particularly in
the process of egress of differentiated erythrocytes from the bone marrow, which is
discussed further in Chapter 5.
3.6.4 Src-family kinases
Src-family kinases are protein tyrosine kinases activated following engagement of sev-
eral different classes of cellular receptors, including integrins. Upon activation, some
SFK are known to localize to focal adhesions and activate signaling molecules such as
paxillin [76]. SFKs mutant animals have demonstrated hematopoietic and erythroid-
specific defects, and specific SFK family members have been shown to provide pro-
tection from apoptosis in hematopoietic cells, which led to the hypothesis that they
may play an important role in integrin-dependent erythropoiesis.
Treatment of TER119+ cells with a SFK inhibitor led to a dose-dependent in-
hibition of cell expansion. Quantitative PCR expression profiling studies indicated
that Lyn and Hck were the most highly expressed members in fetal liver cells, so
they were chosen for further study. The IP-Western approach utilized, however, did
not indicate that either of these kinases is specifically activated by the presence of
fibronectin during integrin-dependent erythropoiesis. One important caveat is that
the kinase activity of these proteins is regulated by a combination of phosphoryla-
tion and dephosphorylation events, so assaying for total phosphotyrosine, as above,
may not provide an accurate measure of protein activation. A fluorometric kinase
assay was also used to assess activity but the differences in activity level between
fibronectin-stimulated and control samples was too small to be significant (data not
shown).
The evidence from other groups that Lyn plays a role in erythropoiesis is very
strong. Lyn -/- erythroblasts displayed a defect in upregulation of TER119 as well as
decreased expansion capacity [31]. In addition, Lyn -/- erythroid cells had decreased
levels of GATA-1 and Stat5, key erythroid transcription factors [29]. While I can-
not conclude from the experiments presented above that Lyn or Hck are activated
in response to fibronectin binding during integrin-dependent erythropoiesis, further
experiments are needed before a definitive statement can be made. In particular, all
of the studies indicating a role for Lyn in erythropoiesis were done with knockout
mice; it could be that the reagents available to study Lyn activation directly are not
sensitive enough to detect the relevant differences. Exploration of integrin-dependent
erythropoiesis in Lyn knockout mice is certainly one area of future work.
3.6.5 Conclusion
In this chapter, I present data to establish that a4# 1 integrin functions as a bona fide
signaling receptor in the second phase of erythropoiesis. One of its major functions is
to prevent differentiating erythroid cells from apoptosis through upregulation of bcl-
xl, much like the action of Epo binding to its receptor on early erythroid progenitors.
a,5,31 integrin does not play a similar survival role, consistent with the idea that it
functions only as an adhesion receptor. In addition, the signals downstream of a 4#1
integrin in erythroid cells capture many of the hallmarks of canonical integrin signal-
ing, including activation of the focal adhesion kinase protein Pyk2 and cytoskeletal
adaptor protein paxillin. Linking these signals to cellular behavior is a focus of future
work, as discussed in Chapter 5.
Chapter 4
Role of Integrins in Hematopoietic
Stem Cell Maintenance
4.1 Introduction
Hematopoietic differentiation is a unidirectional process. Once an HSC receives the
appropriate differentiation cues, it follows a path of progressive lineage commitment
until it reaches its terminal phenotype. At each developmental stage, a unique com-
bination of signals from cytokines, stromal cells and the extracellular matrix converge
to determine cell fate. The contribution of cytokines to this milieu are traditionally
the most well studied, but recent progress in defining the stem cell niche has focused
the field on the role of stromal cells and, to a lesser extent, extracellular matrix. One
of the aims of my thesis was to explore the role of ECM in directing HSC self-renewal
and differentiation decisions. This chapter presents my work on identifying highly
expressed integrins on purified populations of HSCs and characterizing the role of
those integrins in mediating HSC adhesion to ECM proteins.
4.2 ECM in the HSC niche
The extracellular matrix in the bone marrow serves two functions. The first is a
structural role, where the complex three dimensional network created by the van-
ety of ECM molecules expressed in the bone marrow serves to trap and concentrate
soluble factors, protecting them from proteolytic cleavage, and also to attract spe-
cific cell types to interact with each other. However it is clear that ECM molecules
themselves can also present important developmental cues in many tissues, including
the hematopoietic system. Here I summarize the roles of three bone marrow ECM
molecules in hematopoietic development.
4.2.1 Tenascin-C
Tenascin-C is a large disulfide linked extracellular matrix molecule that plays an
important role in morphogenesis. Tenascin-C is expressed at epithelial-mesenchymal
junctions during development, playing an especially important role in neurogenesis,
skeletogenesis and vasculogenesis. In the adult, it is expressed during processes such
as wound healing, nerve regeneration and tissue involution [30]. Tenascin-C has a
hexabrachion structure, with each monomer comprised of several functional domains,
including EGF-like repeats, a series of fibronectin type III domains and a fibrinogen
globe at the terminal knob. Tenascin-C can have both adhesive and anti-adhesive
effects on cells, and may also stimulate proliferation in hematopoietic cells [69]. The
av#3 and ag31 integrins are known to function as receptors for tenascin-C.
The expression pattern of tenascin-C in developing embryos suggests a specific
interaction with HSCs. In day 34 human embryos, tenascin-C expression was found in
a specific region of the ventral mesoderm beneath the dorsal aorta [46]. This staining
was found only in the portion of the mesoderm closest to rounded CD34+ cells within
the dorsal aorta, while other ECM proteins such as fibronectin showed more uniform
expression both around the dorsal aorta and in more rostral and caudal sections. This
morphological polarity suggests that tenascin-C may interact with developing HSCs
in a way that induces or preserves the mechanism of asymmetrical divisions that lead
to stem cell self renewal, as in Drosophila spermatogenesis [89].
Suppression of hematopoietic activity in tenascin-C knockout mice provides fur-
ther evidence of an important role in stem cell maintenance. The colony forming
capacity of bone marrow cells from tenascin-C knockout mice was significantly lower
than that of normal mice [50]. Furthermore, bone marrow stromal cells derived from
the knockout mice had a decreased ability to support hematopoietic cells derived
from normal mice, as measured by cell number (cobblestone assay) and colony form-
ing ability of the nonadherent cells. The addition of soluble tenascin-C rescued the
supportive ability of tenascin-C deficient stromal cells in a dose-dependent manner.
Though by no means definitive, these studies suggest a close interaction between
tenascin-C and hematopoietic cells in a way that helps to maintain stem cell activity.
4.2.2 Collagen
Collagens are the most abundant proteins in the animal kingdom, and thus comprise
the extracellular matrix of nearly every tissue [43]. The structure of collagen con-
sists of three coiled chains wound in a characteristic triple-helix. Collagen type I was
found to be one of the major ECM components of bone marrow [49]. Immunofluo-
rescence studies indicated high expression of collagen I in both compact bone as well
as trabecular bone, where HSCs have been shown to reside [93]. Collagen I is also
the major ECM protein secreted by osteoblasts, further indicating a potential role for
this particular matrix protein in regulation of stem cell self-renewal. Integrins of the
31 subfamily including a1, a20 1, a301, aio1, and a 1 31 are known to function as
collagen receptors, although a1#1 and a201 are the most widely expressed.
In a recent study of the role of the calcium-sensing receptor (CaR) in the HSC
niche, the Scadden group found that while CaR knockout mice had normal numbers
of HSCs, the retention of these cells in the bone marrow was impaired [2]. CaR
knockout mice had fewer HSCs in the bone marrow but an abnormally high number
in the circulation, suggesting a defect in localization to the endosteum. The authors
show that the knockout cells also have impaired adhesion to collagen type I, thereby
indicating that as a mechanism for retention of HSCs in the endosteal niche.
4.2.3 Laminin
Laminins are extracellular matrix glycoproteins that comprise all basement mem-
branes. Laminins are heterotrimers comprised of varying a, /, and y chains. Five
a, three /, and three y chains have been identified and so far 12 of the theoretically
possible 45 different heterotrimers have been clearly identified [78]. Laminin-1, made
of ai, f1, and 71 chains, is the first discovered and most well characterized form.
All laminin isoforms have the same basic cross-shaped structure, with three short
arms and one long arm, with molecular weight around 820 kDa. Integrins of the #1
(a1 #31, a 2 0 1 , a3 01, a6 0 1 , a 7 #1, ag#1) and av (a,03, a,05, a,0s) subfamilies are re-
ported to function as laminin receptors, though with differing specificities and tissue
distribution [7].
The localization pattern of laminin isoforms within the bone marrow suggests a
close interaction with developing hematopoietic cells at different stages. Immunoflu-
orescence staining with monoclonal antibodies to different laminin chains revealed
that the a4 chain was expressed in intersinusoidal spaces in adult mouse bone mar-
row, suggesting that laminins containing the a 4 chain such as laminin-8 may be the
preferred isoform interacting with HSCs [24]. A developmentally regulated shift in
the localization of the a5 chain was also observed. Whereas the a 5 chain is expressed
in the arteriolar walls and subendothelial basement membrane in the adult, its ex-
pression is restricted to the arteriolar walls in the bone marrow of the newborn. This
postnatal shift could suggest a role for a 5 chain-containing laminins such as laminin-
10 and laminin-11 in trafficking of mature blood cells across the sinusoidal membrane
and hence an adhesion preference for more differentiated cells over HSCs.
4.3 HSC Purification Strategies
The history of hematopoietic stem cell purification from bone marrow is essentially
that of finding a needle in a haystack, as HSCs occur at a frequency of about 1 in
100,000 bone marrow cells [95]. The development of the spleen colony assay by Till
and McCulloch in 1961 provided the first technique to quantify stem cell behavior in
vivo. The initial study was done by injecting whole bone marrow cells intravenously
into lethally irradiated recipients and counting the number of proliferating colonies
seen on the spleen, termed CFU-S [77].
The earliest efforts to separate stem cells were based on physical characteristics
such as size and density. Using velocity sedimentation, the observation was made in
1969 that smaller bone marrow cells were more likely to produce secondary CFU-S,
thought to be the result of proliferation of primitive cells. Later, building upon the
finding that quiescent cells were smaller than proliferating cells, cell-cycle active drugs
were used to isolate quiescent cells as purified populations of HSCs. At this time, in
the mid-1970s, the best possible purification led to a 30-fold enrichment in CFU-S
activity [57]..
In the late 1970s, the development of new technologies to separate cells in addition
to more sensitive techniques to assess their function in vivo completely revolutionized
stem cell science. The fluorescence-activated cell sorter (FACS) enabled researchers
to analyze and collect individual cells on the basis of their cell-surface markers. In
1977 the competitive repopulation assay was introduced as a more sensitive assay
of stem cell activity than the CFU-S [1]. In this assay, now the gold standard for
quantification of in vivo stem cell behavior, purified populations of stem cells are
injected intravenously into lethally irradiated recipients. The donor cells are marked
genetically and can be distinguished from recipient cells by highly specific monoclonal
antibodies. Using FACS analysis, the contribution of the donor cells to the blood
lineages of the recipient mouse can be assessed at short and long times post transplant
and the purity of the starting population can be calculated using Poisson statistics.
Over the next 20 years, several cell surface proteins were identified as stem cell
markers on the basis of their ability to enrich bone marrow populations for the most
primitive cells. By the early 1990s, the most well accepted stem cell population was
the so-called KTLS population, selected by the phenotype of c-Kit+ (stem cell factor
receptor), Thy-1.1" (CD90, a thymocyte marker), lineage- (markers for differen-
tiated cells including B cells, T cells, granulocytes, platelets and erythrocytes) and
Sca-1+ (sten cell antigen 1). This population yields a 2000-fold enrichment over
whole bone marrow, as measured by the competitive repopulation assay [57]. Of im-
portance is the fact most of these stem cell markers were empirically determined, and
that with the exception of c-kit, the receptor for stem cell factor, expression of these
markers has not been functionally linked to stem cell maintenance.
In addition to cell surface markers, supravital stains have also been used to isolate
HSCs. The two most commonly used stains are Hoechst 33342, used to separate a
side population of bone marrow cells highly enriched in stem cell activity [21] and the
mitochondrial dye rhodamine-123 [72]. Using a combination of previously established
cell-surface markers, supravital stains, and endoglin, a stem cell marker identified
in the Lodish lab, the purity of bone marrow derived HSC populations has been
narrowed to 1 in 3 [12].
More recent advances in HSC purification have come from the use of the SLAM
family of proteins as HSC markers [34]. This purification strategy takes advantage of
a family of receptors that are differentially expressed among functionally distinct pro-
genitor cells. Using gene expression profiling, highly purified HSCs were identified as
CD150+CD244-CD48 while more committed progenitors are CD244+CD150-CD48~
and the most restricted progenitors are CD48+CD244+CD150-. Competitive recon-
stitution analysis indicated that 1 in 2.1 CD150+CD48~Sca-1+lineage c-kit+ cells
were true long-term repopulating HSCs, the best purification to date.
4.4 Integrin Expression
4.4.1 Identifying highly expressed integrins
I decided to use the endoglin+ Sca-1+ rhodamine"o' HSC phenotype for my studies
because at the time it represented the most pure population of stem cells. These cells
are purified from bone marrow by first gating a Sca-1 and endoglin double positive
population. Of these cells, the bottom 1% of rhodamine low or negative cells were
further gated. The frequency of these cells in whole bone marrow is roughly 1 in
100,000 [12]. A sample of the flow cytometry gating schemes is shown in Figure 4-1.
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Figure 4-1: Flow cytometry gating scheme for sorting Sca-1+ endoglin+
rhodaminelw HSCs. After gating on live bone marrow cells, Sca-1 and endoglin
double positive cells are gated (left panel). Of this population, the bottom 1% of
rhodamine low or negative cells are further gated (right panel).
To asses integrin expression on these cells, I used a flow cytometry strategy similar
to that used to assess integrin expression on fetal liver erythroid progenitors. In this
case, bone marrow cells were isolated and stained for the HSC markers as described
above. Cells were also incubated with biotinylated primary antibodies against a panel
of integrin subunits and then with PE Cy5.5- conjugated streptavidin. Cells were
gated into a Sca-1+ endoglin+ rhodaminel" population, and PE Cy5.5 fluorescence
was examined within this population. Cells that had PE Cy5.5 expression two orders
of magnitude above the background staining of the secondary antibody alone were
scored as positive (Figure 4-2).
Due to limiting numbers of cells, a subset of these highly expressed integrin sub-
units were chosen for further analysis. I decided to focus on expression of a2, av, a9,
#1 and 33 integrins because these subunits were not only differentially expressed in
HSC and WBM populations, but also because they form receptors for extracellular
matrix proteins relevant to the HSC niche. More specifically, a 2,31 is a receptor for
collagen type I and both a,33 and ago1 bind to tenascin-c and laminins.
Integrin expression was further analyzed by real time PCR. Sca-1+ endoglin+
rhodaminel'" cells were sorted and total RNA was isolated. Because of the very
small number of cells used (on order of thousands) in each experiment, carrier RNA
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Figure 4-2: Expression of integrin subunits on purified HSCs and whole
bone marrow. Flow cytometry was used to compare integrin expression on Sca_+
endoglin+ rhodamine'o HSCs to that on unfractionated bone marrow. Expression
of integrin subunits two orders of magnitude above the background staining of the
secondary antibody alone was scored as positive.
was used in the isolation. The amount of carrier RNA was then subtracted from
the total RNA concentration prior to reverse transcription. Primers to each integrin
subunit were generated and primer efficiency was calibrated against genomic DNA
samples (data not shown). As shown in Figure 4-3, a1, as, #1 and #3 integrins are all
highly expressed relative to whole bone marrow. Expression of a 2 integrin was four
orders of magnitude greater in HSCs than in WBM. In order to accurately represent
the very high expression level of a 2 integrin in HSC, in Figure 4-4, a 2 expression is
shown relative to other highly expressed integrin subunits.
4.4.2 Focus on a 2 integrin
The very high expression level of a 2 integrin on HSCs relative to whole bone marrow
as well as to other highly expressed integrin subunits led me to further focus on
this particular subunit. Using a strategy previously used in the Lodish lab [92], I
examined a2 integrin expression among lineage Sca-1+ endoglin+ and lineage- Sca-
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Figure 4-3: a, as, #1, and 33 integrins are highly expressed on purified
HSCs. Quantitative PCR was used to assess integrin expression on Sca-+ endoglin+
rhodamine" HSCs. Expression levels were normalized to expression of 18S ribosomal
RNA as well as to unfractionated bone marrow. 2 ng total RNA input was used in
each case.
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Figure 4-4: a2 integrin is highly expressed on purified HSCs. Quantitative
PCR was used to assess integrin expression on Sca-+ endoglin+ rhodamine1O HSCs
relative to other highly differentially expressed integrins. a2 integrin expression on
HSCs is an order of magnitude greater than a, and as integrin.
1+ endoglin- populations. Lineage- cells are a population of progenitor cells depleted
for mature cells of each of the myeloid, lymphoid and erythroid lineages. Previous
work has shown that all of the long term repopulating ability is found within the
lineage- Sca-1+ endoglin+ population [12], so I compared integrin expression in this
population with that in lineage- Sca-1+ endoglin~ via quantitative PCR. As shown
in Figure 4-5, the lineage- Sca-1+ endoglin+ population has 7-fold higher a2 integrin
expression relative to the lineage- Sca-1+ endoglin- population, indicating that a2
integrin is expressed on purified HSCs with long term repopulating ability.
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Figure 4-5: Expression of a2 integrin in lineage- Sca-1+ endoglin+ and
lineage- Sca-1+ endoglin- populations. Quantitative PCR analysis indicated
that a2 integrin is highly expressed on lineage- Sca-1+ endoglin+ cells relative to
lineage- Sca-1+ endoglin- cells.
I also used flow cytometry to further analyze a 2 integrin expression. Bone marrow
cells were stained with antibodies to lineage markers, endoglin, Sca-1 and a 2 integrin.
The lineage- Sca-1+ population was gated and a 2 integrin expression was compared
in the endoglin- and endoglin+ subpopulations among these cells. The frequency of
these cells is very low in total bone marrow, so hundreds of millions of total bone
marrow cells must be analyzed in order to collect data on a large enough population
of HSCs. The flow cytometer data acquisition software program that is used in
conjunction with the MoFlow3 Cytometer does not have the ability to save files
with more than one million data points so in order to be able to analyze very large
populations of cells, I saved the flow cytometer data in small truncations. Each
one of these subpopulations represents on order hundreds of HSCs. As shown in
the histograms in Figure 4-6, in every case expression of a 2 integrin is greater in
the lineage- Sca-1+ endoglin+ population than in the lineage- Sca-1+ endoglin-
population. These data indicate preferential expression of a 2 integrin on HSCs over
other hematopoietic progenitor cells.
4.5 HSC-Extracellular Matrix Adhesion
In order to determine the functional significance of integrin expression on HSCs, I
adapted a centrifugal force detachment assay to measure HSC adhesion to extracel-
lular matrix proteins. (Appendix A)
Because of the focus on a20 1 integrin, as described above, I was interested to test
adhesion of HSCs to collagen type I, an a20 1 ligand and also a major ECM protein in
the bone marrow niche. As discussed in Appendix A, optimal centrifugation speeds
were determined using whole bone marrow and fetal liver cell populations. Next, I
tested HSC-adhesion to a range of collagen concentrations. Freshly isolated Sca-1+
endoglin+ rhodaminelow cells (on order hundreds/well) were added to plates coated
with 1, 10 or 100 pg/ml collagen type I in 100 pL serum-free media. After 30-60
minutes incubation at 37 C, the cells were the photographed, inverted and centrifuged
and then photographed again. The fraction of adherent cells was quantitated using
ImageJ image analysis software. The data indicate a direct relationship between
collagen concentration and HSC adhesion (Figure 4-7). The middle collagen coating
concentration of 10 pg/ml was chosen for all further experiments.
I tested the role of a2,31 integrin in mediating HSC-collagen adhesion by incubating
cells with 20 pg/ml a2 integrin function-blocking antibody before the adhesion assay.
As shown in Figure 4-8, the majority of HSCs were adherent to 10 pg/ml collagen
I after detachment at 1000g. In five independent experiments, this adhesion was
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Figure 4-6: Expression of a 2 integrin in lineage- Sca-1+ endoglin+ and
lineage- Sca-1+ endoglin- populations. Flow cytometry analysis indicated that
a 2 integrin expression is greater on lineage~ Sca-1+ endoglin+ cells than on lineage-
Sca-1+ endoglin- cells. In each plot, the filled histogram represents a 2 integrin ex-
pression on lineage- Sca-1+ endoglin- cells and the unfilled histogram is expression on
lineage- Sca-1+ endoglin+ cells. Each histogram represents data from on order hun-
dreds of lineage- Sca-1+ endoglin+ cells and thousands of lineage- Sca-1+ endoglin-
cells, representing the relative frequencies of these populations in bone marrow.
Figure 4-7: Adhesion of Sca-1+ endoglin+ rhodamine"' HSCs to collagen
type I at 1000g. Adhesion of Sca-1+ endoglin+ rhodamine" HSCs to 1, 10 and
100 pg/ml collagen type I was measured using a centrifugal force detachment assay.
There is a direct relationship between collagen concentration and HSC adhesion. Each
bar represents the average of average of 2-3 experiments.
significantly reduced in the presence of the a 2 integrin antibody. Because of the
variation in the basal level of adhesion, likely due to the inherent impurities in the
stem cell population and the very small numbers of cells utilized, these data were
normalized and averaged. As shown in Figure 4-9, addition of a 2 integrin blocking
antibody significantly reduced the level of HSC adhesion to collagen type I. Together,
these data show that a 20 1 integrin mediates HSC adhesion to collage type I.
4.6 Discussion
Hematopoietic stem cells develop in highly specific microenvironments where a com-
bination of signals from soluble factors, stromal cells and extracellular matrix come
together to support self-renewal and differentiation, the definitive processes of any
stem cell. While the contributions of soluble factors and stromal cells have tradition-
ally been the focus of studies of the HSC niche, extracellular matrix-derived signals
are only now being studied. To begin to build a knowledge base of ECM-HSC inter-
actions, I focused on the role that integrins play in the HSC niche.
Despite major advances in the past decade, the precise molecular definition of a
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Figure 4-8: Adhesion of Sca-1+ endoglin+ rhodaminelow HSCs to collagen is
mediated by a2 integrin. Addition of 20 pg/ml a 2 integrin function-blocking anti-
body blocked adhesion of Sca-1+ endoglin+ rhodaminelow HSCs to 10 pg/ml collagen
at 10OOg in 5 experiments.
Figure 4-9: Summary of HSC adhesion to collagen. The presence of a 2 integrin
function-blocking antibody partially abrogates HSC adhesion to collagen. Asterisks
indicate significance at the level of p <0.01.
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hematopoietic stem cell is still a relatively open question in stem cell biology. The
combination of supravital dyes and cell surface markers has led to the isolation of
increasingly purified populations, but the lack of a functional significance of these
markers is a major hindrance. In addition, the inability to definitively know the stem
cell potential of a given population without transplantation is another challenge.
Because integrins have a very clear functional role in mediating adhesion and can
also function as signaling receptors, identification of those integrins that are highly
expressed on stem cells and the biological significance of that expression could result
in the discovery of a functional marker in addition to yielding new insights about
stem cell regulation.
Using flow cytometry and quantitative PCR, I identified a2 integrin as an integrin
subunit that is highly differentially expressed on HSCs versus whole bone marrow.
Furthermore, its expression on rhodamine'" Sca-1+ endoglin+ cells is greater than
even other highly differentially expressed integrins. a 2 0 1 integrin forms the major
receptor for type I collagen, which is secreted by osteoblasts. Given the identification
of osteoblasts as important regulators of the HSC niche, I hypothesized that the high
expression of a 20 1 integrin on HSCs serves to mediate adhesion to collagen and thus
either bring HSCs in close contact with osteoblasts or transmit self-renewal signals
itself or both.
To test this hypothesis, I first measured adhesion of highly purified HSC popu-
lations to collagen and other ECM proteins. I found that adhesion to collagen was
relatively higher than to other ECM proteins. Furthermore, there was a direct rela-
tionship between HSC adhesion and collagen concentration. Treating HSCs with a
function-blocking antibody to a2 integrin significantly reduced the level of adhesion
to collagen.
An important next step to verify that a 2 integrin is a bona fide HSC marker
is to do a competitive repopulation experiment. The Weissman group has already
done this experiment, transplanting a+ lineage-/" Thyl.11o Sca-1+ c-kit+ and a-
lineage-/" Thy1.1'" Sca-1+ c-kit+ HSC populations into irradiated recipients [83].
By analyzing the contribution of the donor cells to each of the hematopoietic lineages
up to 21 weeks post transplant, they determined that a+ lineage-/" Thyl.1o Sca-1+
c-kit+ represent a short term repopulating phenotype. Their overall conclusion is that
a 2 integrin selectively marks a subset of primitive HSCs which retains multilineage
repopulating potential but exhibits reduced self-renewal capacity.
The critical factor in analyzing their work is that the antibody they used to detect
a 2 integrin expression and to sort HSCs for transplantation is a function-blocking
antibody. This has several implications for their results. First, the lack of long term
repopulation in the a2 population could be a result of a defect of these cells to home
to and/or engraft in the appropriate niche. A short term homing assay done by the
same group using the same function-blocking antibody to a2 integrin indicates that
there is no homing defect [82]. Lineage-/l" Thyl.11o Sca-1+ c-kit+ GFP+ cells were
incubated with and without the function-blocking a 2 integrin antibody and injected
into irradiated recipients. Three hours later, bone marrow was harvested and the
frequency of GFP+ cells was determined using flow cytometry. Their data show a
similar frequency of GFP+ cells in control and antibody-treated animals, indicating
that blocking a2 integrin on HSCs does not lead to a homing defect to the bone
marrow. However, this experiment does not preclude the possibility of an engraftment
defect. Indeed, as my data show, a 2 integrin mediates adhesion of HSCs to collagen,
which is present in the bone marrow niche. Distinct from homing or engraftment, a2
integrin could also have an explicit role in the stem cell niche by transmitting signals
necessary for self-renewal. Given this understanding of the Weissman work, it cannot
be concluded that a2 integrin-expressing HSCs are not true long term repopulating
stem cells.
The proper experiment to determine the role of a2 integrin in stem cell self-renewal
is a transplant experiment in which populations of highly purified HSCs expressing a2
integrin are injected with and without treatment with a function-blocking antibody.
Although this experiment will not be able to distinguish between engraftment and
intrinsic self-renewal effects, a positive result will motivate further investigation.
In conclusion, the main point of this chapter is that a2 integrin is highly expressed
on highly expressed populations of HSCs, and mediates adhesion to collagen type I,
an important matrix protein in the bone marrow niche. A definitive conclusion re-
garding the repopulating ability of a 2 integrin-expressing HSCs cannot be drawn until
a competitive repopulation transplant is performed with HSCs with fully functioning
a 2 integrins. Other future experiments regarding the role of integrins in the HSC
niche are discussed in Chapter 5.
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Chapter 5
Future Directions
5.1 Integrin-mediated signal transduction in ery-
thropoiesis
5.1.1 Coordination of erythropoietin- and a40 1 integrin-mediated
signals
The work presented in Chapter 2 and 3 establishes a two-phase model for regulation
of erythropoiesis by growth factor and integrin-mediated signals. While coordinated
signaling by growth factors and integrins together control cell behavior in a number of
other contexts, my finding is unique in that signals appear to dominate in temporally
restricted regimes, with the early steps of erythropoiesis regulated by binding of
Epo to its cognate receptor and the later steps by engagement of a401 integrin by
fibronectin. Determining the biological significance of such regulation is one area of
further exploration.
An open question is this area is how Epo signaling in the first phase leaves ery-
throid cells in a state receptive to integrin signaling in the second phase. My finding
that engagement of a4/1 in the first phase is not sufficient to support terminal ery-
throid cell expansion, despite the presence of Epo, indicates either that the signals
generated by a401 integrin in early erythroblasts are short lived or that the proper
signals are not generated in those cells. These hypotheses could be tested by com-
paring a401 integrin-mediated signals in early erythroblasts and later, differentiating
cells. One challenge is that survival of early erythroblasts in the absence of Epo is
compromised, so in the early cells, Epo-mediated signals and a40 1 integrin-mediated
signals will necessarily be intertwined. By comparing the signaling profile of early ery-
throblasts with Epo alone, it might be possible to begin to determine the contribution
of integrins at this phase.
Systematic testing of the various signaling molecules involved in Epo- and a40 1 in-
tegrin signaling is required to parse these pathways. While the traditional immunoblot
method is certainly feasible for this type of study, one of its limitations is that it can
give only average, population-level results. In this system, the input cells, the early
erythroblasts derived from fetal liver, are not a completely homogeneous population
and likewise their responses to stimulation by Epo, in terms of differentiation and
expansion, are heterogeneous as well. By developing flow cytometric assays for key
signaling molecules in the pathways of interest - for example, phosphorylated JAK2,
STAT5 or Akt - single-cell level resolution can be achieved [56]. Furthermore, by cou-
pling these types of assays with CD71 and TER119 staining, the differentiation state
of each cell can be correlated with signaling molecule expression. This could provide
a powerful tool to examine signal transduction in erythropoisis at higher resolution.
Other systems-level analyses using microarrays could also provide useful information
on the set of genes stimulated by Epo and a401 integrins at different stages.
5.1.2 Hsp70 and apoptosis
One interesting aspect of caspase-3 activation is that it occurs during normal erythro-
poietic differentiation as well as during apoptosis [90]. During apoptosis induced by
Epo starvation, one of the targets of activated caspase-3 is GATA-1, a key erythroid
transciption factor. During normal erythroid differentiation, however, GATA-1 re-
mains uncleaved by caspase-3 and is thus able to activate transcription of erythroid
genes. It was recently established that the heat shock protein Hsp70 co-localizes with
GATA-1 in the presence of Epo to protect it from cleavage and thus promote cell
survival. [61]
Because of the similarities between Epo-mediated and integrin-mediated protec-
tion form apoptosis, one area of ongoing work is to test the hypothesis that integrin
engagement in the second phase of erythroid culture also leads to Hsp70 protection of
GATA-1. Ribeil et al used unfractionated human umbilical cord blood cells cultured
in a cytokine cocktail in order to generate erythroid progenitors, a system very differ-
ent from the fetal liver cells that I use. Therefore it is first necessary to repeat their
finding that the presence of Epo leads to Hsp70 mediated protection of GATA-1 by
immunoprecipitating GATA-1 from TER119+ cells cultured in the presence and ab-
sence of Epo and assessing Hsp70 expression by Western blot. Preliminary evidence
shows that this is indeed the case in the fetal liver system (data not shown). Next, this
same experiment will be done in cells in the second phase of erythropoiesis cultured
on fibronectin-coated or control substrates. Finally, in order to link the association of
Hsp70 and GATA-1 to downstream apoptotic behavior, the nuclear export inhibitor
leptomycin B can be used to sequester Hsp70 in the nucleus in apoptotic conditions.
Thus it is predicted that the in absence of fibronectin, which would normally lead to
apopotosis, administration of leptomycin B would result in greater cell survival.
5.1.3 Egress of differentiated erythrocytes from bone mar-
row
Under normal homeostatic conditions, the bone marrow is the site of erythropoiesis
in the adult. There is a large body of work characterizing the numerous biochemical
and morphological changes that take place during the course of erythropoietic differ-
entiation, in addition to mechanistic data on the signals underlying these processes,
of which this thesis is a part. Once erythroid cells have terminally differentiated
and enucleated, they must egress the bone marrow in order to enter the circulation.
Surprisingly, there is a dearth of knowledge of the mechanism and regulation of this
process.
One of the conceptual motivations for this thesis was the idea that adhesive inter-
actions on hematopoietic cells are dynamic, responding to the unique needs of cells
at distinct developmental stages. As discussed in Chapter 2, one possible biological
explanation for the downregulation of integrin subunits on differentiated erythroid
cells is to minimize adhesive interactions as cells prepare to enter the circulation. In
parallel, there is new evidence that Epo signaling upregulates expression of the sialo-
mucin podocalyxin during differentiation and that circulating reticulocytes retain
podocalyxin expression [66]. Podocalyxin has been shown to have an anti-adhesive
role in some contexts, and decrease in its expression level leads to abnormal reten-
tion of reticulocytes in the bone marrow. Together these data provide support for
the conceptual framework posed above. Identifying other genes that are differentially
expressed between differentiated erythroid cells and early erythroblasts may provide
other clues in this continuum.
The study of what role integrins may play in transendothelial migration of dif-
ferentiated red blood cells in the bone marrow is a natural extension of my work.
Of the many changes that take place during erythroid differentiation, modulation of
mechanical properties is critical to bestowing the differentiated erythrocyte with the
elasticity needed to traverse narrow capillaries [85]. Through their connections to the
cytoskeleton, integrins display exquisite inside-out and outside-in signal transduction
capabilities. Likewise, they have a noted role in mechanotransduction in many other
systems [32]. Although their expression is downregulated during the course of ery-
thropoisis, the most differentiated population of fetal liver cells, the R5 cells, still
do express a 40 1 integrins above background level, and it is possible that signaling
pathways initiated by these receptors on these cells or perhaps even in earlier stages
play a role in regulating transendothelial migration.
5.2 Role of integrins in HSC maintenance and dif-
ferentiation
5.2.1 Endosteal niche
As discussed above, osteoblasts have recently been identified as important regulators
of the HSC niche in vivo [9, 93]. However the mechanism by which they do so has not
yet been determined in any detail. One potential mechanism is that membrane-bound
Jagged-i on the surface of osteoblasts activates the Notch signaling pathway in HSCs
[9]. Notch signaling regulates many developmental cell fate decisions, including stem
cell self-renewal in vivo and in vitro [13]. Genetically increasing the number of os-
teoblasts in vivo led to increased expression of Jagged 1, which led to a concomitant
increase in the level of activated Notch in HSCs. Moreover, blocking Notch cleavage
with a y-secretase inhibitor reduced the ability of stromal cells to support HSC ac-
tivity [9]. Given the data presented in Chapter 4 showing that a 2 integrin specifically
mediates adhesion of HSCs to collagen, one possible model for the role of a 2 integrin
in the osteoblastic HSC niche is that through adhesion to collagen, it brings HSCs in
a position to interact with membrane-bound Jagged-1 on osteoblasts.
Evidence supporting this model comes from recent studies of calcium-sensing re-
ceptor (CaR) knockout mice. The Scadden group found that while CaR knockout
mice had normal numbers of HSCs, retention of these cells in the bone marrow was
impaired [2]. CaR knockout mice had fewer HSCs in the bone marrow but an ab-
normally high number in the circulation, suggesting a defect in localization to the
endosteum. The authors show that the knockout cells also have impaired adhesion
to collagen type I, thereby indicating that as a mechanism for retention of HSCs in
the endosteal niche
There are several ways to test this hypothesis. First, as discussed in Chapter 4,
the logical next step is to transplant a2 HSCs with and without pre-treatment with
an a 2 integrin function-blocking antibody into irradiated recipients and monitor the
contribution of the donor cells to each of the hematopoietic lineages over a period of
6 months. In the meantime, in vitro experiments exploring the role of a2 integrin
in the osteoblastic niche could be conducted. As shown by Calvi et al, co-culture
of purified HSCs with osteoblasts supports expansion of LTC-ICs, possibly though
activation of Notch signaling in HSCs. This experiment could be repeated in the
presence of function-blocking antibodies to a 2 integrin and expansion of LTC-ICs
and Notch activation could be measured.
Another possible connection between integrins and Notch signaling comes from
primary neural stem cells, where activation of #1 integrin leads to cleavage of the
Notch intracellular domain and subsequent translocation to the nucleus [11]. This
suggests that a similar mechanism could be at play in the HSC niche, where adhesion
of HSCs via a 2 and potentially other #1 integrins could lead to additional activation
of the Notch signaling pathway. One way to test this hypothesis is to assay for
Notch activation in adherent and non-adherent populations of HSCs. Similarly, Notch
activation could be assayed after treatment with function blocking antibodies for #1 or
other integrins. Finally, the presence of Mn++ cations is known to activate integrins.
A simple test would be to incubate stem cells in the presence and absence of Mn++
and then assay for Notch activation.
5.2.2 Vascular niche
Recent models of the HSC niche provide for dynamic interactions with bone marrow
components. While the endosteal niche may be the preferred microenvironment for
quiescence, the vascular niche may be better suited for differentiation and mobilization
[38]. Much is unknown about the vascular niche, in particular at what stage cells take
residence there and at what stage they transition to a new niche. The work presented
above has focused on the role of integrins the endosteal niche in self-renewal, but
there could also be a role for integrins in the vascular niche as well.
Rolling of hematopoietic progenitor cells along bone marrow endothelium is medi-
ated by selectins as well as by interactions between a401 integrins and VCAM-1 [47].
However, little is known about what downstream signaling pathways are activated
by this interaction, and what role they play in HSC differentiation. Furthermore,
the vascular niche is rich with cytokines and their effects are likely modulated by
integrin signaling as well. For example, stromal-derived factor 1 (SDF-1) is required
for efficient homing of circulating HSCs, as well as for transdendothelial migration
[55], and it also increases adhesion of hematopoietic progenitor cells to VCAM-1 [54].
In particular, integrin-mediated interactions with laminins may be an important
mechanism for differentiation or trafficking of HSCs in the vascular niche. As dis-
cussed in Chapter 4, laminins are expressed in arteriolar walls of the bone marrow.
By careful identification of the cells present in the vascular niche and characteriza-
tion of the set of integrins they may express, a model for how these interactions may
influence differentiation can be constructed.
5.3 Discussion
Hematopoietic stem cells hold great promise for the future treatment of disease. De-
spite decades of progress, however, there are still many challenges before the full
therapeutic potential of these cells can be realized. Studying the interactions of
hematopoietic cells with their local microenvironments is one promising avenue of
inquiry. Precise characterization of the "adhesome" - the set of genetic, morpho-
logic and biochemical changes mediated by adhesion to the extracellular matrix - of
hematopoietic cells can lead to design of better ex vivo expansion systems as well as
uncover fundamental properties of self-renewal and differentiation decisions.
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Appendix A
Development of Centrifugal Force
Detachment Assay
A.1 Introduction
Because of the fundamental importance of cell-matrix adhesion there are a number of
different adhesion assays reported in the literature. Aside from substrate preparation
and incubation times, which are specific to system under study, the main experimental
parameters are the methods of cell detachment and quantification. The simplest
detachment method is to aspirate the media and nonadherent cells with a pipette.
Although these wash assays provide a quick, qualitative assessment of cell adhesion,
they are limited by a lack of sensitivity and repeatability, due to the application of
uneven, unknown forces. The importance of flow in many physiological conditions led
to protocols using shear forces to detach cells. A variety of devices including a parallel
plate flow chamber, a spinning disk apparatus and a high throughput microfluidic
chamber have been used to quantify cell adhesion [45].
These methods, though highly quantitative, require specific equipment, which
can be expensive. A method that resolves the drawbacks of the wash assay and flow
assay is the centrifugation assay [25]. The use of a centrifuge to detach cells ensures
uniformity and repeatability, while maintaining simplicity and requiring no specialized
equipment. In addition, the normal force experienced by the cells can be calculated,
and many conditions can be tested at once using multiwell plates. Quantification of
the adherent and nonadherent cells can also be done in several different ways. In
addition to manual counting, fluourescence and spectrophotometric methods can also
be used to quantitate cells.
I adapted the centrifugation assay for the specific application of quantitating adhe-
sion of hematopoietic cells to matrix proteins. The primary challenge was optimizing
assay conditions for use with a very small number of cells, as necessitated by HSC
studies. In addition, the adhesive properties of a given population of cells are relative
to the assay context. The major determinants of adhesion, substrate concentration
and detachment force, create many possible assay environments wherein cell behavior
may be very different. While by no means an exhaustive sampling of the full exper-
imental space, data generated in assay development and optimization are presented
below.
A.2 Fetal Liver Adhesion Studies
One important assay parameter to be determined was the detachment force applied
to the cells. The centrifugal force detachment assay applies a centrifugal force to
populations of adherent cells. Experimentally, the applied force can be varied by
varying the centrifugal speed according to the following relationship:
Fce11 RCF - V - (pceii - Pmedium)
RCF oc w - rc
where V is the volume of the cell, pcell is the density of the cell, Pmedium is the density
of the medium, RCF is the relative centrifugal force, w is the centrifugal velocity and
rc is the radius of the centrifugation.
After observing a developmentally regulated change in integrin expression on fe-
tal liver erythroid cells, I was interested in measuring adhesion of these cells to fi-
bronectin. I first tested the adhesion of the R1+R2 and R5 populations cells to
one concentration of fibronectin under a range of detachment forces. The R1+R2
population had the highest integrin expression and was thus predicted to be more
adhesive than the R5 population, which had low integrin expression. At low and high
centrifugal detachment forces, there was no little difference in adhesion of the two
populations (Figure A-1). It is likely that the adhesion seen at low detachment force
is due to nonspecific factors, while the application of high force is enough to sever
all attachments to the substrate. At the intermediate level of 1000g, the detachment
force is enough to detect differences between the most and least adhesive populations
while at the same time leaving some dynamic range on the low end of adhesion.
As further illustration of this point, the effect of function-blocking antibodies was
tested at two centrifugal accelerations. At 1000g, it was possible to discern a clear
abrogation in adhesion of all cell populations (Figure A-2). At 1800g, however, the
effect of the antibody on R4 and R5 populations was obscured by the very high
detachment force. Therefore 10OOg was used in all further adhesion assays.
1.2
1
0.8T
' ~ 0.6
ME 0.4
0.2
01[
1g 55g 450g 10OOg 1800g 2800g
centrifugal acceleration
Figure A-1: Effect of detachment force on adhesion of fetal liver erythroid
cells. R1+R2 and R5 populations of fetal liver cells were sorted and their adhesion to
10 pg/ml fibronectin was assessed at a range of centrifugal accelerations correlating
to a range of detachment force. Application of low and high detachment force did not
detect differences in adhesion of the two cell populations, but application of interme-
diate force resulted in statistically significant differences in adhesion. One asterisk
indicates significance at the level of p<0.05 and two asterisks indicate significance at
the level of p<0.01.
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Figure A-2: Effect of function-blocking antibody on adhesion of R1+R2
cells. R1+R2 cells were incubated with 10 pg/ml function-blocking antibody against
a4 integrin and adhesion to 10 pg/ml fibronectin was assessed at two centrifugal
accelerations correlating to different detachment force. At the high detachment force,
the low level of adhesion of R4 and R5 cells obscures the effect of the antibody. Lower
detachment force allows for a dynamic range in even the least adhesive populations.
A.3 Bone Marrow Adhesion Studies
The very small number of purified HSCs that could be readily obtained presented a
challenge in testing a large number of adhesion conditions. Some preliminary studies
were carried out using freshly isolated unfractionated bone marrow cells as a close
substitute.
Once a protocol was determined, I tested adhesion of purified HSCs to two concen-
trations of fibronectin, laminin 10/11 and tenascin-C. The data in Figure A-3 shows
that the assay technique is sensitive enough to detect differences in HSC adhesion
to substrates at various concentrations. However, more optimization is needed to
acquire biologically meaningful data for each of these substrates. For example, the
range of fibronectin concentrations tested here is too high, as indicated by a lack of
difference in adhesion over one order of magnitude concentration. For laminin and
tenascin, however, the data indicate that the low concentration is within the dynamic
range.
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Figure A-3: Adhesion of HSCs to fibronectin, laminin and tenascin. Sca-
1+ endoglin+ rhodamine"o"' cells were sorted from bone marrow directly into plates
pre-coated with the indicated concentrations of fibronectin (F), laminin10/11 (L) and
tenascin-C (T). Fraction of cells adherent after centrifugal acceleration at 10OOg is
shown. The range of fibronectin concentrations is too high, but the low concentrations
of laminin and tenascin appear to be within the dynamic range. These data are the
averages of 2-3 experiments, each done in triplicate.
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Appendix B
Materials and Methods
B.1 Chapter 2
Animals C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor,
ME) and maintained at the Whitehead Institute animal facility.
Fetal liver erythroid progenitor cells C57BL/6 E14.5 fetal livers were dis-
sected into Hanks Balanced Salt Solution containing 2% fetal bovine serum, 100
units/ml penicillin, 100 pg/ml streptomycin and 10mM HEPES at pH 7.4 (called
HBSS+) at a concentration of 2 livers per ml. Liver tissue was disaggregated by vig-
orous pipetting followed by passage though a 70 tm cell strainer. Cells were blocked
with a 1:50 dilution of ChromPure Rat IgG (Jackson Laboratory) and labeled with a
1:200 dilution of PE TER119 and FITC CD71 antibodies (Pharmingen, San Diego,
CA) for 15 minutes on ice. Cells were washed and resuspended in HBSS+ and labeled
with 1 pg/ml propidium iodide for cell sorting on a MoFlow3 Cell Sorter. (Becton
Dickinson)
in vitro erythroid culture Day 14.5 fetal livers were suspended in PBS+2%FBS
at a concentration of 2 fetal livers/ml. Cells were incubated with 1:50 rat IgG for 15
minutes on ice, followed by 1:100 biotinylated anti-Ter119 antibody. (Pharmingen).
Cells were washed, resuspended at the same concentration and further labeled with
1:10 tetrameric streptavidin complex (StemCell Technologies) for 15 minutes, fol-
lowed by 60 pl magnetic colloids per milliliter of cells (StemCell Technologies) for 15
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minutes. TER119- cells were purified using a StemSep magnetic column (StemCell
Technologies) according to manufacturers instructions. Cells were then seeded into
24-well plates coated overnight with 0.5 ml of 20 pg/ml human plasma fibronectin,
V, Vo, or VRGD- recombinant fusion proteins and washed twice with PBS. Cells
were seeded at a density of 100,000 cells/ml. For the first 16-18 hours, they were
cultured in "Day 1" media, which consists of Iscove's Modified Dulbecco's Medium
(IMDM) (Gibco) supplemented with 15% FBS (StemCell Technologies, Vancouver,
BC), 1% BSA (StemCell), 10 pg/ml recombinant human insulin (Sigma), 200 pg/ml
recombinant human holo-transferrin (Sigma), 10-4 M #-mercaptoethanol, 1% peni-
cillin/streptomycin, 2 mM glutamine and 2 U/ml erythropoietin (Amgen, Thousand
Oaks, CA). After 16-18 hours, the medium was changed to "Day 2" media, which con-
sists of IMDM supplemented with 20% FBS (Invitrogen), 10-4 M #-mercaptoethanol,
1% penicillin/streptomycin and 2 mM glutamine. At each time point, cells were dis-
sociated with PBS containing 5 mM EDTA and 10% FBS for 5 minutes at 37'C.
Cells were counted using a hemocytometer and then stained with 1:200 FITC CD71
and PE TER119 for 15 minutes on ice. Cells were washed and then analyzed used
a Becton Dickinson FACS Calibur flow cytometer. FACS data were analyzed using
FlowJo 6.0. (Tree Star, Inc., Ashland, OR)
In experiments where the substrate was varied from Day 1 to Day 2, cells were
cultured as above for the first day, dissociated with PBS containing 5 mM EDTA and
2% FBS for 5 minutes at 37 C, counted using a hemocytometer, and added to fresh
plates coated with 20 pg/ml human plasma fibronectin or Vo or VRGD- recombinant
fusion proteins in Day 2 media. After 24 hours in culture, cells were dissociated and
counted as described above.
In experiments utilizing TER119+ cells, E14.5 fetal livers were blocked and la-
beled with biotinylated TER119 antibody as above. Cells were then washed, re-
suspended in HBSS+ and incubated with streptavidin-coupled microbeads (Miltenyi
Biotec, Auburn, CA) according to manufacturers instructions. TER119+ cells were
isolated on an autoMACS column (Miltenyi Biotec) using the Possels program.
Recombinant fibronectin proteins Recombinant fibronectin fusion proteins
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were expressed in E.coli grown to late log phase and induced with 1mM isopropyl-
b-D-thiogalactopyranoside for 4 hours. Cells were harvested by centrifugation and
stored at -80 *C in PBS containing a cocktail of protease inhibitors (Sigma). Bacterial
pellets were thawed and the buffer was adjusted to 50 mM sodium phosphate pH 8.0,
10 mM imidazole, 300 mM NaCl. Pellets were incubated with 2 mg/ml lysozyme and
DNase for 30 minutes at 4C, lysed using a French press, brought to 1% Triton-X100,
and centrifuged at 20,000g for 20 minutes. Supernatants were incubated with TALON
resin (Clontech), washed in 50 volumes of wash buffer (50mM sodium phosphate, pH
8.0, 300 mM NaCl, 10 mM imidazole), and proteins were eluted with 2 volumes of
elution buffer (wash buffer adjusted to 250 mM imidazole). Proteins were dialysed
against CAPS buffer (20 mM CAPS, pH 11.0, 150 mM NaCl). The final protein
concentrations were determined by UV absorption and protein sizes were confirmed
on SDS-PAGE.
Integrin expression C57/B16 E14.5 fetal livers were dissected and stained as
above with the addition of a 1:100 dilution of the following biotinylated anti-integrin
antibodies, all from Pharmingen: a 2 (DX5), a 4 (9C10), a5 (5H10-27), a, (RMV-
7), /1 (Ha2/5), #2 (C71/16) and #1 (2C9.G2). Cells were washed, resuspended and
stained with 1:1000 streptavidin PE Cy5.5 (Caltag Laboratories, Burlingame, CA)
for 15 minutes on ice. Cells were washed, resuspending in HBSS+ and labeled with
1 pg/ml propidium iodide for FACS analysis. Data was collected on a MoFlow3 Cell
Sorter (Becton Dickinson) and analyzed with FlowJo 6.0.
For quantitative PCR analysis, E14.5 fetal liver cells from R1-R5 populations were
sorted and total RNA was isolated using an RNeasy Micro Kit. (Qiagen, Valenica,
CA) RNA was reverse-transcribed using SuperScript II RT (Qiagen) using random
primers. SYBR Green real-time PCR was performed on an Applied Biosystems Prism
7000 machine with primers designed using Primer Express 2.0 (Table B.1).
Adhesion assays 96-well half-area plates (Costar, Corning, NY) were pre-coated
with various concentrations of human plasma fibronectin (Sigma-Aldrich, St. Louis,
MO) diluted in PBS overnight at 4 C and washed twice with PBS before cell seeding.
5000 freshly sorted fetal liver R1-R5 erythroid progenitors were resuspended in 100
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Table B.1: Quantitative PCR Primers for a4, a5 and #1 integrins.
Gene Forward Primer Reverse Primer
a4 CGTGCGAGACATCCTTACCC CCAAGGTGGTATGTGGCCTC
a 5  GGACTTCCCATCTGACTCCG CTGGCAAGACCAAAGATGCAT
01 CTGCTGGTGTTTTCCACGG TTTCCCATCTCCAGCAAAGTG
18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA
tl Alpha Modified Essential Medium (Gibco, Carlsbad, CA) and added to each well.
Cells were incubated at 37 C for 30 minutes. To perform the adhesion assay, wells
were filled to the top with medium and covered with clear sealing tape (Costar), en-
suring no entrapped air bubbles. Plates were inverted and spun at the various speeds
in for 5 minutes. Each well was photographed and the number of cells enumerated
before and after spinning. Fraction adherent was calculated as the number of cells
present in each well after spinning divided by the number of cells present before spin-
ning. Cells were enumerated using ImageJ image analysis software. Each condition
was carried out in triplicate for each adhesion experiment.
The force experienced by the cells is given by:
Fcei= RCF - V - (Pcell - Pmedium)
RCF oc w - rc
where V is the volume of the cell, pcell is the density of the cell, Pmedium is the density
of the medium, RCF is the relative centrifugal force, w is the centrifugal velocity and
rc is the radius of the centrifugation. In our centrifuge, rc was 10 cm.
For integrin-inhibition studies, cells were incubated with 10 pg/ml of the following
function blocking antibodies prior to cell seeding: a 4 clone PS/2 (Serotec, Raleigh,
NC), a5 clone 5H10-27 (Pharmingen) and 01 clone Ha2/5 (Pharmingen). Cells were
stained for 15 minutes at 4 C.
Statistical Analysis Significance levels for adhesion and apoptosis data were
determined using the Students t-test algorithm in Microsoft Excel using a two-tailed
distribution. (Redmond, WA) In cases where the same samples were subject to
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different treatments, a homoscedastic two-tailed distribution was used. In cases where
different samples were subject to the same treatment, a heteroscedastic two-tailed
distribution was used.
VCAM-1 binding assay R1+2 through R5 populations were sorted as described
above. Cells were washed with 5 mM EDTA in PBS and then incubated with in-
creasing amounts of VCAM-1-k (RD Systems, Inc) in the presence of 1mM MnCl2
for 30 minutes at 4 C. Unbound VCAM-1-k was removed by two washes (also in
the presence of 1mM MnCl 2) and cells were incubated with 1:100 FITC-conjugated
goat anti-mouse anti-VCAM-1 antibody (Caltag) for 30 minutes at 4 C. BInding was
quantitated on a FACS Calibur Flow Cytometer. At least 10,000 cells were analyzed
for each value plotted. Background binding, determined by incubating cells from each
population with each concentration of VCAM-1-k in the presence of 5mM EDTA, was
subtracted for each value.
B.2 Chapter 3
Cell Cycle Analysis Cell cycle analysis was performed by pelleting cultured cells
at each time point and resuspending them in 500 pl HBSS+. Cells were fixed with
the addition of 1.5ml ice cold ethanol for one hour at 4 C. Cells were then washed
two times at a high centrifugation rate in order to avoid the loss of flocculent cells.
Cells were then incubated in 500 pl of the following staining solution for three hours
at 4 C: 3.8 mM sodium citrate, 50 pg/ml propidium iodide and 0.5 pg/ml RNAse A
(Qiagen). Data were then collected with a FACS Calibur flow cytometer and analyzed
using ModFit LT(Verity Software House).
Apoptosis Assay In order to measure apoptosis, TER119- cells were isolated
and cultured as above on uncoated surfaces in the presence of Epo for 16-18 hours.
At this time, cells were dissociated as above, washed and incubated with 10 pg /ml
function blocking antibodies to either a 4 (Serotec, Raleigh, N.C, clone PS/2) or a5
(Pharmingen, 5H10-27) integrin for 15 minutes on ice. The cells were then transferred
to fresh fibronectin or control substrates in Epo-free Day 2 media. Four hours after
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Epo-removal, cells were dissociated and stained with annexin V-APC (BD Pharmin-
gen) and 7-AAD (BD Pharmingen) according to manufacturers instructions. Bcl-xL
expression was assayed by fixing and permeabilizing the cells and then staining with
1:500 antibody to bcl-xL (Cell Signaling Technology, clone 54H6) for 15 minutes at
room temperature followed by 1:1000 AlexaFluor 647 secondary for 15 minutes at
room temperature. (Molecular Probes, Carlsbad, CA) Expression data were then
collected on a FACS Calibur flow cytometer and analyzed using FlowJo. Cells were
gated based on FSC and SSC properties before then analyzing annexin V and 7-AAD
levels.
Bcl-xl Expression TER119- cells were isolated as above and cultured in Dayl
media on uncoated surfaces overnight. Cells were then dissociated and serum starved
in IMDM+1%BSA for one hour before being transferred to fresh fibronectin or un-
coated wells. At the indicated time points, cells were lysed in modified RIPA buffer
(50 nM Tris pH 7.4, 250 nM NaCl, 2nM EDTA, 0.5% NP-40) containing protease in-
hibitors (Complete mini (Roche), 4mM NaF, 4mM Na3 VO4 ) for 20 minutes at 4 0C.
Lysates were ultracentrifuged at 13,000g for 10 minutes at 4 *C and then analyzed via
SDS-PAGE. Membranes were blocked with Odyssey Blocking Buffer (Li-COR Bio-
sciences, Lincoln, NE) for one hour and then incubated with 1:1000 bcl-xL antibody
clone 54H6 (Cell Signaling Technology, Danvers, MA) and 1:1000 actin antibody 1-19
(Santa Cruz Biotechnology) overnight. Proteins were visualized using the Odyssey
infrared imaging system (LI-COR Biosciences).
For flow cytometry analysis, cultured cells were dissociated with PBS with 5
mM EDTA and 2% FBS and pelleted. Cells were fixed in 3.7% formaldehyde for
15 minutes at room temperature and washed once. Cells were permeabilized in ice
cold methanol for 30 minutes on ice. After washing, cells were resuspended in 100
pl HBSS+ and incubated with 1 pl bcl-xL antibody (same as above) for 1 hour at
room temperature. After washing, cells were incubated with 1:100 AlexaFluor 647
anti-rabbit antibody (Molecular Probes). Background staining was determined by
incubation with the secondary antibody alone.
For quantitative PCR analysis, the primers shown in Table B.2 were used:
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Table B.2: Quantitative PCR Primers for bcl-xl.
Gene Forward Primer Reverse Primer
bcl-xL ATGGACTGGTTGAGCCCATC CCCGGTTGCTCTGAGACATT
18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA
Caspase-3 Caspase-3 expression was assessed by flow cytometry. Cells were dis-
sociated, fixed and permeabilized as above. Each sample was resuspended in 100 Pl
HBSS+ and stained with 0.5 pl cleaved caspase-3 antibody C92-605 (Pharmingen)
for 30 minutes at room temperature. Cells were washed once and stained with 0.5 Pl
Alexa 647 secondary antibody in 100 pl HBSS+ for 30 minutes at room temperature.
Paxillin and Pyk2 For quantitative PCR analysis, the primers shown in Table
?? were used:
Table B.3: Quantitative PCR Primers for FAK and Pyk2.
Gene Forward Primer Reverse Primer
FAK CCTTCCTGTCCCTCCTACCC GGTGGCATGCAAAGGAAGA
Pyk2 GCATGTGGGAGATCCTCAGC TTTCGAGCCAGAAGAAAGGC
18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA
Pyk2 activation was assessed by Western blot. Cells and lysates were prepared as
above. Membranes were blotted with an anti-phosphoPyk2 antibody (Tyr 402) from
Cell Signaling. GAPDH (6C5, Research Diagnostics, Inc) was used to normalize Pyk2
expression.
Paxillin activation was assessed via immunoprecipitation and Western blot. Lysates
were prepared as above and pre-cleared with 25 pl protein A beads for 1 hour at 4 C.
Pre-cleared lysates were incubated with 4 pl paxillin antibody (2452, Cell Signal-
ing) overnight at 4 C. Proteins were bound to 25 pl protein A beads for 1 hour at
4 C and eluted as above. Membranes were blotted with anti phospho-paxillin an-
tibody (Tyr118, Cell Signaling) and anti paxillin antibody. For Pyk2 and paxillin
co-immunoprecipitation experiments, 4 pg Pyk2 antibody form Upstate was used.
SFKs
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To test the effect of SFKs on erythroid cell expansion, increasing concentrations of
the SFK inhibitor PP2 and its inactive analogue PP3 were incubated with TER119+
cells for 5 minutes at room temperature before being added to fibronectin coated
plates. Equal volumes of DMSO were used as an added control.
For quantitative PCR analysis, the primers shown in Table B.5 used:
Table B.4: Quantitative PCR Primers for SFKs.
Gene Forward Primer Reverse Primer
Src CAAGGTGCCAAATTCCCCAT TCGGTCAGCAGAATCCCAAAG
Fyn TCACTTTCCATCCGTGATTGG GGCCCGCGTTGTGATATAGTA
Hck CAACAAGCACACCAAAGTGGC ACCAGTTTGTCATGCTGCAGC
Lck ATCCCACGATTCAGCGCTT GCCCCAACATCAGACATCCTA
Fgr TGGAACTGCAGCACAAAGGTG TGCCTCAGCAGCTTCATGATC
Lyn CCAACCTCATGAAGACCTTGC ACCCTTAGCCATGAACTCGGT
18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA
For SFK immunoprecipitations, 4 pg Hck antibody 06-833 (Upstate) and 4 pg
Lyn antibody 2732 (Cell Signaling) were used.
B.3 Chapter 4
HSC staining Integrin Expression Bone marrow cells were stained with the same
anti-integrin antibodies as above. In addition, an a9 antibody was obtained from
Dean Sheppard at UCSF.
For quantitative PCR analysis, the primers shown below (Table B.5) were used in
addition to the ones noted above:
Adhesion Assay In order to block a 2 integrin, 10pg/ml of function-blocking
antibody Hal/29 (BD Pharmingen) was used.
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Table B.5: Additional Quantitative PCR Primers for integrin subunits.
Gene Forward Primer Reverse Primer
a2 GCATCTCTGACCTGATCCTGG GAGTTTGAATGGCTGGCAGC
av AGAGGCAAGAGCGCAATCC AACGTCTCGGTCCACAGCAG
ag GGTCTTCGAGGCCTTGCAC CACCCCACAACGTAGCCAC
#2 AGCAGTCCTTTGTCATCCGG GCACGGTCACTGTATCCGTG
#3 TCACCAATATCACCTACCGGG GAGAGTCCCACGGTCCTGG
18S GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA
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